[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4254
1. Yu M, Zheng H, Tsuneyama K, Takahashi H, Nomoto K, Xu H, Takano Y: Paradoxical expression of maspin in gastric carcinomas: correlation with carcinogenesis and progression. Hum Pathol; 2007 Aug;38(8):1248-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paradoxical expression of maspin in gastric carcinomas: correlation with carcinogenesis and progression.
  • To clarify the role of maspin in the genesis and progression of gastric carcinomas, its expression pattern and level were studied by immunohistochemistry on tissue microarrays containing gastric carcinoma (n = 237), normal gastric mucosa (n = 23), intestinal metaplasia (n = 38), and adenoma (n = 42); and the findings were compared with clinicopathological parameters.
  • Furthermore, maspin expression in the gastric carcinoma cell lines (HCG-27, MKN28, and MKN45) was examined by immunohistochemistry and Western blotting.
  • We found that cytoplasmic and nuclear maspin expression paralleled each other (P < .05) and decreased from intestinal metaplasia, adenoma, and carcinoma to normal gastric mucosa (P < .05).
  • Univariate and multivariate analyses indicated that expression of maspin correlated negatively with cumulative patient survival in gastric carcinoma (P < .05) but was not an independent factor in the prognosis.
  • Our study indicated that maspin expression experiences upregulation in gastric precancerous lesions and then slight downregulation with malignant transformation.
  • High expression may paradoxically promote invasion and metastasis of gastric carcinomas and could be considered a good marker for the pathobiological behaviors of gastric carcinomas.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma / pathology. Biomarkers, Tumor / metabolism. Precancerous Conditions / pathology. Serpins / metabolism. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cytoplasm / metabolism. Cytoplasm / pathology. Disease Progression. Female. Fluorescent Antibody Technique, Direct. Humans. Lymph Nodes / pathology. Male. Metaplasia. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Stomach / metabolism. Stomach / pathology. Survival Rate. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17490717.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


2. Atsumi T, Fujisawa S, Tonosaki K: Relationship between intracellular ROS production and membrane mobility in curcumin- and tetrahydrocurcumin-treated human gingival fibroblasts and human submandibular gland carcinoma cells. Oral Dis; 2005 Jul;11(4):236-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Curcumin is a well-known chemopreventive agent of oral cancers as well as stomach and intestinal cancers.
  • METHODS: The intracellular ROS production and membrane mobility by curcumin or TH-curcumin were measured in human submandibular adenocarcinoma cells (HSGs) and human primary gingival fibroblasts (HGFs).
  • [MeSH-major] Adenocarcinoma / metabolism. Curcumin / analogs & derivatives. Curcumin / pharmacology. Membrane Fluidity / drug effects. Oxidants / pharmacology. Reactive Oxygen Species / metabolism. Submandibular Gland Neoplasms / metabolism

  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15984955.001).
  • [ISSN] 1354-523X
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antioxidants; 0 / Oxidants; 0 / Reactive Oxygen Species; 00U0645U03 / tetrahydrocurcumin; IT942ZTH98 / Curcumin
  •  go-up   go-down


3. Minematsu H, Saito Y, Kakinoki R, Andoh A, Kushima R, Fujiyama Y: Evaluation of mucin expression patterns in gastric borderline (group III) lesions. J Gastroenterol; 2006 Jun;41(6):547-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of mucin expression patterns in gastric borderline (group III) lesions.
  • BACKGROUND: Recommendations for diagnosis and treatment of gastric borderline (group III) lesions remain controversial.
  • METHODS: Sixty-three gastric lesions were histopathologically identified as belonging to group III on the basis of an endoscopic forceps biopsy.
  • All of the patients underwent endoscopic resection, and the lesions were classified into group A (final diagnosis, adenocarcinoma) or group B (final diagnosis, adenoma).
  • RESULTS: The proportion of complete gastric (positive for MUC5AC and MUC6) plus gastric-predominant phenotypes was significantly higher in group A (58.0%) than in group B (18.7%) lesions (P < 0.05).
  • CONCLUSIONS: Immunostaining of forceps biopsy samples for the mucin phenotype may be helpful for diagnosing gastric borderline (group III) lesions.
  • [MeSH-major] Mucins / biosynthesis. Stomach Neoplasms / classification. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Glycoconj J. 1996 Oct;13(5):693-707 [8909996.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jul;3(7 Suppl 1):S74-6 [16013004.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):166-70 [11668493.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3513-6 [16101171.001]
  • [Cites] Virchows Arch. 2003 Apr;442(4):317-21 [12715167.001]
  • [Cites] Oncology. 2001;61(3):212-20 [11574777.001]
  • [Cites] Cancer. 1994 Dec 1;74(11):2896-907 [7954254.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Virchows Arch. 2002 Mar;440(3):304-10 [11889602.001]
  • [Cites] J Cancer Res Clin Oncol. 1998;124(9):497-502 [9808424.001]
  • [Cites] Endoscopy. 1993 May;25(4):265-8 [8330543.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1427-34 [11745219.001]
  • [Cites] Pathol Int. 2004 May;54(5):311-21 [15086835.001]
  • [Cites] Gut. 1995 Jun;36(6):848-52 [7615272.001]
  • [Cites] Eur J Cancer. 1996 Feb;32A(2):215-20 [8664030.001]
  • [Cites] Chin J Dig Dis. 2005;6(3):119-21 [16045601.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):826-32 [10414502.001]
  • (PMID = 16868802.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


Advertisement
4. Saito H, Fukumoto Y, Osaki T, Fukuda K, Tatebe S, Tsujitani S, Ikeguchi M: Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach. World J Surg; 2006 Oct;30(10):1864-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach.
  • BACKGROUND: Carcinoma arising in the cardioesophageal junction is a distinct clinical entity compared with tumors located in other regions of the stomach.
  • The prognosis for adenocarcinoma of the upper stomach is considered to be relatively poorer than carcinomas of the more distal stomach.
  • We have therefore investigated patients with carcinoma of the gastric cardia in order to evaluate the underlying cause of this poor prognosis.
  • MATERIALS AND METHODS: Clinicopathologic features and postoperative prognosis of 101 patients with carcinoma of the cardia were evaluated and compared with findings on 1884 patients with tumors in other regions of the stomach.
  • RESULTS: Tumors of the cardia had a mean size of 6.8 cm, which was significantly larger than the mean size of 5.9 cm for tumors found in the middle- and lower third of the stomach.
  • The incidence of serosal invasion, lymph node metastasis, and lymphatic and blood vessel invasion was higher in association with adenocarcinoma of the cardia than with adenocarcinoma in remaining parts of the stomach.
  • In the analysis of patients who had undergone curative resection, the 5-year survival rates were 61.6, 79.1, and 82.6% in patients with carcinoma of the cardia, upper one-third, and remaining middle- and lower one-third of the stomach, respectively, and the differences were statistically significant.
  • Multivariate analysis indicated that adenocarcinoma of the gastric cardia is an independent prognostic factor.
  • With regard to the site of recurrence, both lymph node and hematogenous recurrence were observed more frequently in the cardia than in the remaining parts of the stomach.
  • CONCLUSIONS: Our data indicate that the prognosis of patients with adenocarcinoma of the gastric cardia is extremely poor.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia. Gastric Fundus. Neoplasm Recurrence, Local / epidemiology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1995 May;180(5):577-82 [7749534.001]
  • [Cites] Surgery. 1992 Apr;111(4):386-93 [1557684.001]
  • [Cites] Surg Oncol. 1995;4(2):75-81 [7551262.001]
  • [Cites] Cancer. 1992 Aug 1;70(3):569-74 [1623472.001]
  • [Cites] Surgery. 1999 Feb;125(2):195-201 [10026754.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2015-21 [9164213.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):514-9 [7960222.001]
  • [Cites] Jpn J Surg. 1989 May;19(3):290-5 [2779027.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Surgery. 2003 May;133(5):507-11 [12773978.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] J Natl Med Assoc. 1995 Jun;87(6):423-6 [7595964.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • (PMID = 16983479.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Sim HL, Tan KY, Poon PL, Cheng A: Primary rectal signet ring cell carcinoma with peritoneal dissemination and gastric secondaries. World J Gastroenterol; 2008 Apr 7;14(13):2118-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary rectal signet ring cell carcinoma with peritoneal dissemination and gastric secondaries.
  • Disseminated signet ring cell carcinomas frequently arise from the stomach.
  • Biopsy of the lesions revealed signet ring cell adenocarcinoma.
  • Gastroscopy showed multiple nodules with ulceration over several areas of the stomach which were similar in appearance to the colonic lesions.
  • However, no primary tumour of the stomach was seen.
  • Biopsy of the gastric lesions also showed signet ring cell adenocarcinoma.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / pathology. Colonoscopy / methods. Peritoneum / pathology. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Female. Humans. Stomach Neoplasms / secondary

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1975 May-Jun;18(4):332-8 [165050.001]
  • [Cites] Cancer. 2004 May 1;100(9):1776-85 [15112256.001]
  • [Cites] ANZ J Surg. 2001 Dec;71(12):703-6 [11906382.001]
  • [Cites] APMIS. 2000 Jun;108(6):467-72 [11028811.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):183-8 [10981869.001]
  • [Cites] Cancer. 1978 Jun;41(6):2420-5 [207410.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1453-7 [6311394.001]
  • [Cites] Cancer. 1985 Dec 1;56(11):2723-6 [2996745.001]
  • [Cites] Oncology. 1994 Jan-Feb;51(1):30-4 [8265100.001]
  • [Cites] Am J Gastroenterol. 1996 Oct;91(10):2195-9 [8855747.001]
  • [Cites] AMA Arch Surg. 1951 Jan;62(1):79-91 [14789350.001]
  • (PMID = 18395918.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2701538
  •  go-up   go-down


6. Marsman WA, Tytgat GN, ten Kate FJ, van Lanschot JJ: Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. J Surg Oncol; 2005 Dec 1;92(3):160-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction.
  • Tumors of the EGJ can be categorized in two types of cancer divided according to their anatomical origin: distal esophageal adenocarcinoma and adenocarcinoma of the gastric cardia.
  • However, due to their location, in the transitional zone of the esophagus and stomach, there is constant debate about the proper classification, staging, and management of these tumors.
  • The etiology of distal esophageal adenocarcinoma is clearly related to gastroesophageal reflux disease (GERD) and the development of a Barrett's esophagus [2].
  • The etiology of adenocarcinoma of the gastric cardia is less well understood.
  • Special attention will be given to differences and similarities of adenocarcinomas of the gastric cardia and distal esophagus.
  • [MeSH-major] Adenocarcinoma / classification. Cardia. Esophageal Neoplasms. Esophagogastric Junction. Stomach Neoplasms
  • [MeSH-minor] Barrett Esophagus / complications. Diagnosis, Differential. Diet. Gastric Mucosa / pathology. Helicobacter Infections / complications. Helicobacter pylori. Humans. Incidence. Metaplasia. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16299781.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 79
  •  go-up   go-down


7. Wang LB, Jiang ZN, Fan MY, Xu CY, Chen WJ, Shen JG: Changes of histology and expression of MMP-2 and nm23-H1 in primary and metastatic gastric cancer. World J Gastroenterol; 2008 Mar 14;14(10):1612-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes of histology and expression of MMP-2 and nm23-H1 in primary and metastatic gastric cancer.
  • AIM: To investigate the changes of histology and expression of MMP-2 and nm23-H1 in primary and metastatic gastric cancer.
  • METHODS: One hundred and seventy-seven gastric cancer patients with lymph node and/or distal metastasis between 1997 and 2001 were reviewed.
  • Differences in histology of the primary and metastatic gastric cancer were assessed.
  • RESULTS: Poorly and moderately differentiated metastatic gastric cancer was found in 88.7% (157/177) and primary gastric cancer in 75.7% (134/177) of the patients.
  • The histological type of metastatic gastric cancer that was not completely in accordance with the preponderant histology of primary gastric cancer was observed in 25 patients (14.1%).
  • MMP-2 immunoreactivity in metastatic gastric cancer was significantly stronger than that in primary gastric cancer, while nm23-H1 immunoreactivity showed no difference in primary and metastatic gastric cancer.
  • CONCLUSION: Metastatic gastric cancer presents more aggressive histological morphology and higher MMP-2 immunoreactivity than primary gastric cancer.
  • This heterogeneity may elicit a possible mechanism of gastric cancer metastasis.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Matrix Metalloproteinase 2 / metabolism. NM23 Nucleoside Diphosphate Kinases / metabolism. Stomach Neoplasms / enzymology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1996 Jun;23(3):316-24 [8658215.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3263-6 [7614460.001]
  • [Cites] Aust N Z J Surg. 1998 Mar;68(3):180-2 [9563444.001]
  • [Cites] Cancer Lett. 1998 Jun 5;128(1):23-9 [9652789.001]
  • [Cites] J Pathol. 1998 Apr;184(4):401-7 [9664906.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1752-7 [10430079.001]
  • [Cites] J Pathol. 2005 Apr;205(5):623-32 [15726650.001]
  • [Cites] World J Gastroenterol. 2005 Jun 7;11(21):3222-6 [15929171.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):1035-40 [16538217.001]
  • [Cites] World J Gastroenterol. 2006 May 14;12(18):2941-4 [16718824.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • [Cites] Lab Invest. 2000 Mar;80(3):291-301 [10744065.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3944-8 [11051242.001]
  • [Cites] Pathol Int. 2000 Nov;50(11):891-6 [11107065.001]
  • [Cites] Clin Exp Metastasis. 2000;18(4):343-52 [11448066.001]
  • [Cites] Clin Exp Metastasis. 2002;19(1):79-85 [11918086.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):451-6 [15349819.001]
  • [Cites] J Cell Physiol Suppl. 1984;3:99-103 [6589232.001]
  • [Cites] J Natl Cancer Inst. 1988 Apr 6;80(3):200-4 [3346912.001]
  • [Cites] Anticancer Res. 1988 Nov-Dec;8(6):1163-7 [3218952.001]
  • [Cites] JAMA. 1990 Feb 23;263(8):1123-6 [2405205.001]
  • [Cites] J Biol Chem. 1991 May 15;266(14):8784-9 [1851158.001]
  • [Cites] Am J Pathol. 1991 Aug;139(2):245-50 [1714241.001]
  • [Cites] Breast Cancer Res Treat. 1993;24(3):209-18 [8435476.001]
  • [Cites] Jpn J Cancer Res. 1993 Feb;84(2):184-90 [8096503.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;63(4):213-8 [8099459.001]
  • [Cites] Cancer. 1994 Jan 1;73(1):22-7 [8275429.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1597-604 [9108466.001]
  • (PMID = 18330957.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NM23 Nucleoside Diphosphate Kinases; EC 2.7.4.6 / NME1 protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2
  • [Other-IDs] NLM/ PMC2693761
  •  go-up   go-down


8. Ellis MC, Mason T, Barnett J, Kiesow LL, Vetto JT: Gastric malignancies in breast cancer survivors: pathology and outcomes. Am J Surg; 2009 May;197(5):633-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric malignancies in breast cancer survivors: pathology and outcomes.
  • BACKGROUND: As the number of breast cancer survivors increases, the appearance of second malignancies and unusual metastatic patterns likely also is increasing.
  • In particular, we and others have observed gastric malignancies in breast cancer survivors.
  • METHODS: We reviewed 3 regional hospital system tumor databases, comprising 19,049 analytic breast cancer cases, to determine the number, types, and outcomes of subsequent gastric malignancies.
  • RESULTS: Twenty-eight patients developed subsequent gastric malignancies, representing .15% of breast cancer survivors; 82% of patients had gastric symptoms.
  • Twenty-four patients (86%) had gastric primaries and 13 died of their second cancers.
  • Four patients had gastric metastases; all had lobular histology in both their primary tumors and metastatic lesions.
  • CONCLUSION: Gastric symptoms in breast cancer survivors may represent malignant lesions, often second primaries.
  • All gastric metastases in our series were of lobular histology.
  • [MeSH-major] Breast Neoplasms / epidemiology. Neoplasms, Second Primary / epidemiology. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adult. Aged. Female. Gastrointestinal Stromal Tumors / epidemiology. Humans. Lymphoma / epidemiology. Middle Aged. Registries

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19306975.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Sakamoto Y, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T, Katai H, Kosuge T, Sasako M: Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol; 2007 Jun 1;95(7):534-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer.
  • BACKGROUND: The prognosis of patients with liver metastasis from gastric cancer (LMGC) is dismal.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Hepatectomy / mortality. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17219383.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Meimarakis G, Winter H, Assmann I, Kopp R, Lehn N, Kist M, Stolte M, Jauch KW, Hatz RA: Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol; 2006 Mar;7(3):211-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study.
  • BACKGROUND: The effect of Helicobacter-pylori status on survival after curative resection for gastric adenocarcinoma is unknown.
  • We aimed to follow-up patients who were positive or negative for infection with H pylori who had curative (ie, R0) resection for gastric adenocarcinoma to assess differences in relapse-free survival and overall survival.
  • METHODS: Before surgery, we assessed the H pylori status of 166 patients who had R0 resection for gastric adenocarcinoma between 1992 and 2002 with bacterial culture, histological analyses (ie, staining with haematoxylin and eosin and with Warthin-Starry), and serological analyses.
  • [MeSH-major] Adenocarcinoma / microbiology. Adenocarcinoma / surgery. Helicobacter Infections / complications. Stomach Neoplasms / microbiology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2006 May;7(5):364-5 [16648041.001]
  • [CommentIn] Gastroenterology. 2006 Sep;131(3):966-7 [16952569.001]
  • (PMID = 16510330.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


11. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimäki A: MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst; 2009 Jun 3;101(11):793-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
  • However, the clinical relevance of CIP2A to human cancers had not been demonstrated, but the mechanism of its regulation and its clinical role in cancer were completely unknown.
  • METHODS: Tissue microarrays consisting of 223 gastric adenocarcinoma specimens were evaluated for the presence of CIP2A using immunohistochemistry, and the association of CIP2A expression with survival was assessed using Kaplan-Meier analysis.
  • The effects of MYC and CIP2A on each other's expression and on cell proliferation were investigated in several gastric cancer cell lines using small interfering RNAs to CIP2A and MYC and immunoblotting.
  • RESULTS: Expression of CIP2A protein was associated with reduced overall survival for gastric cancer patients with tumors 5 cm or smaller, with a 10-year overall survival in the CIP2A-immunopositive group of 8.1% as compared with 37.6% in the CIP2A-negative group (difference = 29.5%, 95% confidence interval = 12.5% to 46.5%, P = .001).
  • In gastric cancer cell lines, CIP2A depletion led to decreased proliferation and anchorage-independent growth of the cells, as well as to reduced stability and expression of MYC protein.
  • Finally, CIP2A and MYC immunopositivities were associated in gastric cancer specimens (P = .021).
  • CONCLUSIONS: CIP2A immunopositivity is a predictor of survival for some subgroups of gastric cancer patients.
  • CIP2A and MYC appear to be regulated in a positive feedback loop, wherein they promote each other's expression and gastric cancer cell proliferation.
  • [MeSH-major] Adenocarcinoma / chemistry. Autoantigens / analysis. Biomarkers, Tumor / analysis. Feedback, Physiological. Membrane Proteins / analysis. Proto-Oncogene Proteins c-myc / metabolism. Stomach Neoplasms / chemistry


12. Ancona E, Cagol M, Epifani M, Cavallin F, Zaninotto G, Castoro C, Alfieri R, Ruol A: Surgical complications do not affect longterm survival after esophagectomy for carcinoma of the thoracic esophagus and cardia. J Am Coll Surg; 2006 Nov;203(5):661-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: A retrospective analysis was performed on patients with squamous cell carcinoma and adenocarcinoma of the thoracic esophagus and esophagogastric junction, undergoing surgical resection between January 1992 and December 2002.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Cardia. Esophageal Neoplasms / surgery. Esophagectomy / adverse effects. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084327.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Atherton JC: The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol; 2006;1:63-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori is the main cause of peptic ulceration, distal gastric adenocarcinoma, and gastric lymphoma.
  • Host genetic polymorphisms that lead to high-level pro-inflammatory cytokine release in response to infection increase cancer risk.
  • Antral-predominant inflammation leads to increased acid production from the uninflamed corpus and predisposes to duodenal ulceration; corpus-predominant gastritis leads to hypochlorhydria and predisposes to gastric ulceration and adenocarcinoma.
  • However, whether there are disadvantages of an H. pylori-free stomach, for example increased risk of esosphageal adenocarcinoma, remains unclear.
  • [MeSH-minor] Adenocarcinoma / microbiology. Adenocarcinoma / pathology. Duodenal Ulcer / microbiology. Duodenal Ulcer / pathology. Esophagitis, Peptic / microbiology. Esophagitis, Peptic / pathology. Humans. Lymphoma, B-Cell, Marginal Zone / microbiology. Lymphoma, B-Cell, Marginal Zone / pathology. Stomach Neoplasms / microbiology. Stomach Neoplasms / pathology. Stomach Ulcer / microbiology. Stomach Ulcer / pathology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039108.001).
  • [ISSN] 1553-4006
  • [Journal-full-title] Annual review of pathology
  • [ISO-abbreviation] Annu Rev Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 252
  •  go-up   go-down


14. Sjödahl K, Jia C, Vatten L, Nilsen T, Hveem K, Lagergren J: Salt and gastric adenocarcinoma: a population-based cohort study in Norway. Cancer Epidemiol Biomarkers Prev; 2008 Aug;17(8):1997-2001
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salt and gastric adenocarcinoma: a population-based cohort study in Norway.
  • BACKGROUND: Gastric adenocarcinoma is the second leading cause of cancer death worldwide.
  • It has been suggested that consumption of salted foods is associated with increased risk of this cancer, but the results of the few available prospective studies are contradictory.
  • METHODS: A population-based, prospective cohort study in Nord-Trondelag County in Norway during 1984 to 2002 addressed dietary salt intake in relation to risk of gastric adenocarcinoma.
  • Gastric adenocarcinomas were identified in the Norwegian Cancer Registry.
  • RESULTS: Follow-up of 1,122,765 person-years at risk among 73,133 cohort members disclosed 313 incident cases of gastric adenocarcinomas occurring at least 3 years after inclusion into the cohort.
  • There were no statistically significant associations between different levels of salt intake and risk of gastric adenocarcinoma.
  • High consumers of dietary salt were not at increased risk of developing gastric adenocarcinoma compared with low consumers (hazard ratio, 1.0; 95% confidence interval, 0.7-1.4), and no dose-response effect was observed (P(trend) = 0.55).
  • CONCLUSION: High intake of dietary salt does not appear to increase the risk of gastric adenocarcinoma in this low-incidence western population.
  • [MeSH-major] Adenocarcinoma / epidemiology. Sodium Chloride, Dietary. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Sodium.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18708389.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sodium Chloride, Dietary
  •  go-up   go-down


15. Gyorffy H: [Study of claudins and prognostic factors in some gastrointestinal diseases]. Magy Onkol; 2009 Dec;53(4):377-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • I. We explored the changes of CLDN expression in Barrett's esophagus and related adenocarcinoma.
  • Adenocarcinoma showed higher CLDN2 and -3 expression compared with normal and Barrett's epithelia.
  • The similar CLDN expression profile of Barrett's esophagus and adenocarcinoma supports their sequential development.
  • II. Gastric intestinal metaplasia showed higher expression of CLDN2, -3 and -4 as compared with normal antral foveolar mucosa.
  • Colorectal adenoma and adenocarcinoma could not be differentiated according to their CLDN profile.
  • Intestinal metaplasias of Barrett's esophagus and stomach show similar CLDN profile to small bowel epithelium.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Barrett Esophagus / metabolism. Carcinoma, Squamous Cell / metabolism. Child. Child, Preschool. Claudin-3. Female. Fluorescent Antibody Technique. Gastrointestinal Stromal Tumors / metabolism. Gene Expression Regulation, Neoplastic. Hemangiosarcoma / metabolism. Humans. Immunohistochemistry. Leiomyosarcoma / metabolism. Male. Membrane Proteins / metabolism. Middle Aged. Predictive Value of Tests. Prognosis. RNA, Messenger / metabolism. Risk Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20071310.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN3 protein, human; 0 / Claudin-3; 0 / Claudins; 0 / Membrane Proteins; 0 / RNA, Messenger
  •  go-up   go-down


16. Sharma A, Nitharwal RG, Singh B, Dar A, Dasgupta S, Dhar SK: Helicobacter pylori single-stranded DNA binding protein--functional characterization and modulation of H. pylori DnaB helicase activity. FEBS J; 2009 Jan;276(2):519-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori, an important bacterial pathogen, causes gastric ulcer and gastric adenocarcinoma in humans.


17. Azem J, Svennerholm AM, Lundin BS: B cells pulsed with Helicobacter pylori antigen efficiently activate memory CD8+ T cells from H. pylori-infected individuals. Clin Immunol; 2006 Feb-Mar;118(2-3):284-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori infection causes chronic gastritis that may progress to peptic ulcers or gastric adenocarcinoma and thereby cause major world-wide health problems.
  • We further show that the majority of CD8+ T cells in H. pylori-infected gastric mucosa are memory cells, and that memory CD8+ T cells sorted from peripheral blood of H. pylori-infected individuals respond 15-fold more to H. pylori urease compared to memory cells from uninfected subjects.
  • [MeSH-minor] Adult. Cell Proliferation. Cells, Cultured. Gastric Mucosa / immunology. Gastric Mucosa / microbiology. Humans. Middle Aged. Monocytes / immunology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324887.001).
  • [ISSN] 1521-6616
  • [Journal-full-title] Clinical immunology (Orlando, Fla.)
  • [ISO-abbreviation] Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial
  •  go-up   go-down


18. Hou Q, Wu YH, Grabsch H, Zhu Y, Leong SH, Ganesan K, Cross D, Tan LK, Tao J, Gopalakrishnan V, Tang BL, Kon OL, Tan P: Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer. Cancer Res; 2008 Jun 15;68(12):4623-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer.
  • Recurrent genomic amplifications and deletions are frequently observed in primary gastric cancers (GC).
  • RAB23 amplifications in primary gastric tumors were confirmed by both fluorescence in situ hybridization and genomic qPCR, and in two independent patient cohorts from Hong Kong and the United Kingdom RAB23 expression was significantly associated with diffuse-type GC (dGC) compared with intestinal-type GC (iGC).
  • These results provide further evidence that dGC and iGC likely represent two molecularly distinct tumor types, and show that investigating focal chromosomal amplifications by combining high-resolution aCGH with expression profiling is a powerful strategy for identifying novel cancer genes in regions of recurrent chromosomal aberration.
  • [MeSH-major] Chromosomes, Human, Pair 6 / genetics. Polymorphism, Single Nucleotide / genetics. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology. rab GTP-Binding Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Movement. Chromosome Mapping. Chromosomes, Artificial, Bacterial. Cohort Studies. Female. Gene Amplification. Gene Dosage. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genomics. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18559507.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 3.6.1.- / RAB23 protein, human; EC 3.6.1.- / rab GTP-Binding Proteins
  •  go-up   go-down


19. Chang CH, Lin YH, Yeh CL, Chen YC, Chiou SF, Hsu YM, Chen YS, Wang CC: Nanoparticles incorporated in pH-sensitive hydrogels as amoxicillin delivery for eradication of Helicobacter pylori. Biomacromolecules; 2010 Jan 11;11(1):133-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our results indicate that hydrogels are pH-sensitive, leading to protecting nanoparticles from being destructed by gastric acid.
  • Additionally, the incorporation of amoxicillin-loaded nanoparticles in a hydrogel protected the drug from the actions of the gastric juice and facilitated amoxicillin interaction specifically with intercellular spaces, the site of H. pylori infection.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / microbiology. Animals. Chitosan / chemistry. Chitosan / pharmacology. Drug Carriers. Drug Delivery Systems. Gastric Juice / drug effects. Gastric Juice / metabolism. Hydrogen-Ion Concentration. Stomach Neoplasms / drug therapy. Stomach Neoplasms / microbiology. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19924885.001).
  • [ISSN] 1526-4602
  • [Journal-full-title] Biomacromolecules
  • [ISO-abbreviation] Biomacromolecules
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Drug Carriers; 0 / Hydrogels; 804826J2HU / Amoxicillin; 9012-76-4 / Chitosan
  •  go-up   go-down


20. Nakamura K, Yashiro M, Matsuoka T, Tendo M, Shimizu T, Miwa A, Hirakawa K: A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology; 2006 Nov;131(5):1530-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer.
  • BACKGROUND & AIMS: Scirrhous gastric carcinoma carries the highest mortality of all gastric cancers.
  • The aim of the current study is to clarify the possibility of molecular target therapy with Ki23057 for treating scirrhous gastric cancer.
  • METHODS: Five human gastric cancer cell lines were used.
  • In vitro effects of Ki23057 on cell growth were determined by calculating the number of cancer cells.
  • The influences of Ki23057 on the mitogen-activated protein kinase and phosphatidylinositol 3 kinase signaling pathways and the apoptosis pathway in the gastric cancer cells were also examined.
  • Ki23057 significantly inhibited the proliferation of scirrhous cancer cells but not nonscirrhous gastric carcinoma cells.
  • Ki23057 decreased phosphorylation of K-samII/FGF-R2, extracellular signal-regulated kinase, and Akt and increased apoptosis in scirrhous cancer lines.
  • The oral Ki23057 administration significantly (P < .001) prolonged survival of mice with peritoneal dissemination following injection of OCUM-2MD3 scirrhous cancer cells.
  • CONCLUSIONS: A novel K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, appears therapeutically promising in scirrhous gastric carcinoma with K-samII amplification.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Protein Kinase Inhibitors / pharmacology. Quinolines / pharmacology. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Stomach Neoplasms / drug therapy


21. Lee IJ, Lee JM, Kim SH, Chang S, Han JK, Choi BI, Lee HJ, Yang HK, Lee KU: Helical CT evaluation of the preoperative staging of gastric cancer in the remnant stomach. AJR Am J Roentgenol; 2009 Apr;192(4):902-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helical CT evaluation of the preoperative staging of gastric cancer in the remnant stomach.
  • OBJECTIVE: The objective of our study was to evaluate the diagnostic performance of helical CT for evaluating the preoperative staging of gastric cancer in the remnant stomach.
  • MATERIALS AND METHODS: Preoperative helical CT images of 67 patients with gastric cancer in the remnant stomach were independently analyzed regarding staging of the tumor by two radiologists who were blinded to histopathologic and surgical results.
  • The radiologists were asked to determine the depth of tumor invasion of the gastric wall (T stage), classifying it as </= T2, T3, or T4; local lymph node involvement (N stage); and solid organ metastasis or peritoneal involvement (M stage).
  • Three of 18 T4 lesions were understaged because of inadequate gastric distention (n = 1) and misinterpretation of adjacent organ involvement as partial volume averaging (n = 2).
  • CONCLUSION: Contrast-enhanced helical CT can be used successfully to preoperatively evaluate the staging of remnant stomach cancer in patients who have undergone previous gastric resection.
  • [MeSH-major] Adenocarcinoma / radiography. Gastric Stump / radiography. Stomach Neoplasms / radiography. Tomography, Spiral Computed / methods

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304693.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol; 712BAC33MZ / iopromide
  •  go-up   go-down


22. Nashimoto A, Yabusaki H, Nakagawa S, Takii Y, Tsuchiya Y, Otsuo T: Preoperative chemotherapy with S-1 and cisplatin for highly advanced gastric cancer. Anticancer Res; 2009 Nov;29(11):4689-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemotherapy with S-1 and cisplatin for highly advanced gastric cancer.
  • PATIENTS AND METHODS: In total, 120 consecutive patients with highly advanced gastric cancer were treated with S-1 (80 mg/m(2) for 21 consecutive days) and cisplatin (50 mg/m(2) on day 8).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032421.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Kang SH, Kim JI, Moon HS, Kim SH, Sung JK, Lee BS, Jeong HY: [Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma]. Korean J Gastroenterol; 2010 Jan;55(1):26-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma].
  • BACKGROUND/AIMS: We performed retrospective study in order to compare oxaliplatin, leucovorin, and fluorouracil (FOLFOX) versus irinotecan, leucovorin, and fluorouracil (FOLFIRI) in recurred or metastatic gastric adenocarcinoma.
  • METHODS: We investigated 56 patients who were diagnosed with recurred or metastatic gastric adenocarcinoma in a single center during march, 2003 to march, 2008.
  • CONCLUSIONS: Both combination treatment can be used safely and effectively in recurred or metastatic gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098064.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; Folfox protocol; IFL protocol
  •  go-up   go-down


24. Antic T, Staerkel G: Mediastinal epithelioid hemangioendothelioma metastatic to lymph nodes and pleural fluid: report of a case. Diagn Cytopathol; 2010 Feb;38(2):113-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient had a complex history of papillary renal cell carcinoma, papillary thyroid carcinoma, and Waldenstrom's hyperglobulinemia making the diagnosis of metastatic epithelioid hemangioendothelioma difficult.
  • [MeSH-minor] Adenocarcinoma, Papillary / complications. Aged. Biopsy, Fine-Needle. Carcinoma, Renal Cell / complications. Female. Humans. Immunohistochemistry. Kidney Neoplasms / complications. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Stomach Neoplasms / complications. Thyroid Neoplasms / complications. Thyroiditis / complications. Waldenstrom Macroglobulinemia / complications

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688765.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Bal N, Yildirim S, Nursal TZ, Bolat F, Kayaselcuk F: Association of ezrin expression in intestinal and diffuse gastric carcinoma with clinicopathological parameters and tumor type. World J Gastroenterol; 2007 Jul 21;13(27):3726-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of ezrin expression in intestinal and diffuse gastric carcinoma with clinicopathological parameters and tumor type.
  • AIM: To investigate the correlation between ezrin expression and types of gastric carcinoma and clinico-pathological variables.
  • METHODS: We examined ezrin protein expression in 75 gastric carcinoma (53 intestinal types of adenocarcinoma, 22 diffuse types of carcinoma) tissues by immunohistochemistry.
  • RESULTS: Ezrin immunostaining was positive in 43 cases (81.1%) of intestinal type and in 9 (40.9%) cases of diffuse type adenocarcinomas (P < 0.001).
  • In gastric carcinomas, the expression of ezrin protein correlated with the status of H pylori and survival.
  • There was no correlation between expression of ezrin with TNM stage and histological grade of gastric carcinomas (P > 0.05).
  • Furthermore, overexpression of ezrin in carcinomas with H pylori infection may be a genuine specific pathway in which H pylori may cause/initiate gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / chemistry. Cytoskeletal Proteins / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659733.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / ezrin
  • [Other-IDs] NLM/ PMC4250645
  •  go-up   go-down


26. Matono K, Ogata Y, Koufuji K, Aoyagi K, Yano S, Miyagi M, Imaizumi T, Takeda J, Shirouzu K: [A resected case of advanced gastric cancer after treatment with low-dosage TS-1]. Gan To Kagaku Ryoho; 2007 Feb;34(2):253-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A resected case of advanced gastric cancer after treatment with low-dosage TS-1].
  • We report a case of advanced gastric cancer that responded well to low-dosage TS-1.
  • A 72-year-old woman was diagnosed as having unresectable advanced gastric cancer with ascites and hydronephrosis in the right kidney.
  • The postoperative pathological findings showed that the cancer cells were localized to within the mucosa, and there were no cancer cells in the greater and lesser omentum.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Gastrectomy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301538.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


27. Isomoto H, Shikuwa S, Yamaguchi N, Fukuda E, Ikeda K, Nishiyama H, Ohnita K, Mizuta Y, Shiozawa J, Kohno S: Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study. Gut; 2009 Mar;58(3):331-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study.
  • OBJECTIVE: Endoscopic submucosal dissection (ESD) has the advantage over conventional endoscopic mucosa resection, permitting removal of early gastric cancer (EGC) en bloc, but long-term clinical outcomes remain unknown.
  • METHOD: ESD was performed for patients with EGC that fulfilled the expanded criteria: mucosal cancer without ulcer findings irrespective of tumour size; mucosal cancer with ulcer findings <or=3 cm in diameter; and minute submucosal invasive cancer <or=3 cm in size.
  • [MeSH-major] Adenocarcinoma / surgery. Endoscopy / methods. Gastric Mucosa / surgery. Neoplasm Recurrence, Local / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dissection. Early Detection of Cancer. Feasibility Studies. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Treatment Outcome


28. Hwang SW, Lee DH, Lee SH, Park YS, Hwang JH, Kim JW, Jung SH, Kim NY, Kim YH, Lee KH, Kim HH, Park DJ, Lee HS, Jung HC, Song IS: Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol; 2010 Mar;25(3):512-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography.
  • BACKGROUND AND AIM: The aim of this study was to determine the accuracy of endoscopic ultrasonography (EUS) and multidetector-row computed tomography (MDCT) for the locoregional staging of gastric cancer.
  • EUS and computed tomography (CT) are valuable tools for the preoperative evaluation of gastric cancer.
  • For EUS, the early gastric cancer lesions with ulcerative changes had significantly lower accuracy than those without ulcerative changes.
  • CONCLUSIONS: For the preoperative assessment of individual T and N staging in patients with gastric cancer, the accuracy of MDCT was close to that of EUS.
  • Both EUS and MDCT are useful complementary modalities for the locoregional staging of gastric cancer.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20370729.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


29. Schurr PG, Yekebas EF, Kaifi JT, Lasch S, Strate T, Kutup A, Cataldegirmen G, Bubenheim M, Pantel K, Izbicki JR: Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction. J Surg Oncol; 2006 Sep 15;94(4):307-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction.
  • BACKGROUND: Adenocarcinoma of the esophago-gastric junction (EGJ) potentially spreads to abdominal and mediastinal lymph nodes.
  • METHODS: Eighty-five patients with type I and II EGJ cancer underwent curative esophagectomy or esophago-gastrectomy and radical abdominal and mediastinal lymphadenectomy.
  • CONCLUSIONS: Lymphatic microinvolvement shows a high incidence in curatively resected EGJ cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Esophagogastric Junction. Lymph Nodes / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Barrett Esophagus / pathology. Cardia. Esophageal Neoplasms / mortality. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Esophagectomy. Female. Gastrectomy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mediastinum. Middle Aged. Risk. Stomach Neoplasms / mortality. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16917878.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Zhou D, Pan G, Zheng C, Zheng J, Yian L, Teng X: Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues. BMC Cancer; 2008;8:353
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues.
  • The aim of the present study was to reveal the protein expression profile of RON and its relationship with clinicopathological characteristics of gastric carcinoma and prognosis.
  • METHODS: Gastric carcinoma tissue from 98 patients, along with 29 specimens of paraneoplastic tissue and 10 specimens of normal gastric mucosa, were examined by immunohistochemistry (IHC).
  • Western blot analysis of 19 samples of gastric carcinoma tissue and corresponding paraneoplastic tissue, 8 specimens of normal gastric mucosa, and 2 specimens of normal lymph node samples also detected expression of a splice variant of RON, RONDelta165.
  • RESULTS: The rate of positive RON expression differed significantly between gastric carcinoma tissues [56.1%, (55/98)] and paraneoplastic tissues [25.6%, (8/29)] (p = 0.007).
  • In contrast, RON expression was absent in normal gastric mucosa samples.
  • RONDelta165 was strongly expressed in fresh gastric carcinoma tissue, corresponding paraneoplastic tissue, and perigastric lymph nodes with metastatic carcinoma.
  • In contrast, expression of RONDelta165 was not observed in normal gastric mucosa and normal lymph node tissue samples.
  • CONCLUSION: RON expression is significant in gastric carcinoma tissue and corresponding paraneoplastic tissue, but is not expressed in normal gastric mucosa.
  • Expression of RONDelta165 was similarly observed in gastric carcinoma tissue and in metastases present in lymph node tissues.
  • We hypothesize that RON and its splice variant play an important role in the occurrence, progression, and metastasis of gastric carcinoma, and therefore may represent a useful marker to evaluate the biological activity of gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Receptor Protein-Tyrosine Kinases / metabolism. Stomach / metabolism. Stomach / pathology. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Blotting, Western. Female. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Protein Isoforms / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2004 Jan;26(1):4-9 [15059341.001]
  • [Cites] Oncogene. 2003 Jan 16;22(2):186-97 [12527888.001]
  • [Cites] Dig Dis Sci. 2001 Feb;46(2):424-9 [11281194.001]
  • [Cites] Exp Cell Res. 2003 Aug 15;288(2):382-9 [12915129.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1906-14 [15870710.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2222-8 [15788670.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):479-88 [15531916.001]
  • [Cites] Oncogene. 2004 Nov 4;23(52):8464-74 [15378025.001]
  • [Cites] J Clin Invest. 1999 May;103(9):1277-85 [10225971.001]
  • [Cites] Oncogene. 1998 Jun 4;16(22):2927-33 [9671413.001]
  • [Cites] Mol Cell Biol. 1996 Oct;16(10):5518-26 [8816464.001]
  • (PMID = 19040718.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; EC 2.7.1.- / RON protein; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ PMC2629483
  •  go-up   go-down


31. Liu JF, Jamieson GG, Wu TC, Zhu GJ, Drew PA: A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. Ann Surg Oncol; 2009 May;16(5):1397-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia.
  • BACKGROUND: We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia.
  • There was a significant improvement in survival for patients with adenocarcinoma of the cardia on aspirin compared with the two control groups combined (P = 0.029).
  • However, there was no significant difference between the survival curves for T2N0M0 adenocarcinoma patients on aspirin (21) and the two control groups combined (65) (P = 0.29).
  • [MeSH-major] Adenocarcinoma / drug therapy. Aspirin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Cyclooxygenase 2 Inhibitors / administration & dosage. Esophageal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy


32. Cho WJ, Shin JM, Kim JS, Lee MR, Hong KS, Lee JH, Koo KH, Park JW, Kim KS: miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2. Mol Cells; 2009 Dec 31;28(6):521-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2.
  • In this study, we screened various human cancer cell lines including gastric cancer cell lines and found first time that miR-372 is expressed only in AGS human gastric adenocarcinoma cell line.
  • [MeSH-major] Adenocarcinoma / metabolism. MicroRNAs / metabolism. Protein-Serine-Threonine Kinases / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19937137.001).
  • [ISSN] 0219-1032
  • [Journal-full-title] Molecules and cells
  • [ISO-abbreviation] Mol. Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Small Interfering; 0 / Tumor Suppressor Proteins; EC 2.7.1.11 / LATS2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


33. Zhu W, Shan X, Wang T, Shu Y, Liu P: miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer; 2010 Dec 1;127(11):2520-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines.
  • Here, we investigated the possible role of miRNAs in the development of multidrug resistance (MDR) in human gastric and lung cancer cell lines.
  • We found that miR-181b was downregulated in both multidrug-resistant human gastric cancer cell line SGC7901/vincristine (VCR) and multidrug-resistant human lung cancer cell line A549/cisplatin (CDDP), and the downregulation of miR-181b in SGC7901/VCR and A549/CDDP cells was concurrent with the upregulation of BCL2 protein, compared with the parental SGC7901 and A549 cell lines, respectively.
  • Taken together, our findings suggest that miR-181b could play a role in the development of MDR in both gastric and lung cancer cell lines, at least in part, by modulation of apoptosis via targeting BCL2.
  • [MeSH-major] Adenocarcinoma / genetics. Lung Neoplasms / genetics. MicroRNAs / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162574.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN18A microRNA, human; 0 / MicroRNAs; 0 / Proto-Oncogene Proteins c-bcl-2; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


34. Chen J, Cheong JH, Yun MJ, Kim J, Lim JS, Hyung WJ, Noh SH: Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer; 2005 Jun 1;103(11):2383-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography.
  • The current study examined the value of PET for preoperative staging of gastric adenocarcinoma.
  • METHODS: Sixty-eight patients (49 males and 19 females) with gastric adenocarcinoma, who were referred for preoperative FDG-PET scans, were enrolled in this study.
  • The final diagnosis in all patients was made by histologic and surgical findings.
  • RESULTS: For the primary tumor of a gastric adenocarcinoma, PET demonstrated an increased uptake in 64 of 68 patients (sensitivity, 94%), with a mean SUV of 7.0 (range, 0.9-27.7).
  • CONCLUSIONS: FDG-PET improves the preoperative TNM staging of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Stomach Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15856477.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


35. Ren JL, Luo JY, Lu YP, Wang L, Chen JM, Liu M, Shi HX: [Molecular forms of TFF1 in normal gastric mucosa and its relationship with canceration]. Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug;26(8):1234-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular forms of TFF1 in normal gastric mucosa and its relationship with canceration].
  • OBJECTIVE: To study the molecular forms of TFF1 in normal gastric mucosa and its expression in normal, gastric carcinoma, atypical hyperplasia, and intestinalized gastric mucosa.
  • METHODS: The molecular forms of TFF1 in normal gastric mucosa was observed by western blotting.
  • The expression of TFF1 in normal, gastric carcinoma, atypical hyperplasia, and intestinalization gastric mucosa was assayed immunohistochemically.
  • RESULTS: TFF1 existed in normal gastric mucosa in forms of monomer, dimer and 21-kD TFF1 complex, with the last being the richest.
  • TFF1 was expressed mainly in the epithelial cytoplasm of the mucosa in the gastric body and antrum, especially around the nucleus, and the closer to the lumen, the higher the expression.
  • TFF1 expression in the tissues adjacent to gastric carcinoma was higher than that in normal gastric mucosa (P<0.001), and the expression in gastric adenocarcinoma was positively correlated to differentiation of adenocarcinoma.
  • No TFF1 was expressed in poorly differentiated adenocarcinoma.
  • The expression of TFF1 in moderate and well differentiated adenocarcinoma was a little lower than that in normal mucosa (P>0.05).
  • The gastric mucosa with atypical hyperplasia had significantly higher TFF1 expression than normal gastric mucosa (P<0.001), and TFF1 was not detected in intestinalized gastric mucosa.
  • There was no significant difference in TFF1 expression between gastric mucosa around the intestinalized tissues and normal gastric mucosa (P>0.05).
  • CONCLUSIONS: TFF1 plays an important part in protection and restitution of the gastric mucosa, and TFF1 may be related to suppression and differentiation of carcinoma.
  • [MeSH-major] Gastric Mucosa / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Blotting, Western. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939928.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / TFF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


36. Sharma S, Gupta R, Sharma R, Kotru M: Mucin-secreting gastric adenocarcinoma with Rhabdoid areas. Saudi J Gastroenterol; 2010 Jan-Mar;16(1):46-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin-secreting gastric adenocarcinoma with Rhabdoid areas.
  • In this report, we describe the case of a 40-year-old patient with gastric adenocarcinoma composed of histologically well-differentiated glandular areas and focal rhabdoid zones.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasms, Multiple Primary. Rhabdoid Tumor / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 1999;195(12):841-6 [10631720.001]
  • [Cites] Int J Surg Pathol. 2002 Jul;10(3):231-6 [12232582.001]
  • [Cites] Ann Diagn Pathol. 2002 Dec;6(6):357-63 [12478486.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):271-3 [15043320.001]
  • [Cites] Ultrastruct Pathol. 2004 May-Jun;28(3):165-70 [15471430.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1987;411(6):509-14 [2445098.001]
  • [Cites] Pathol Int. 1999 Feb;49(2):160-3 [10355971.001]
  • [Cites] Genomics. 1994 Feb;19(3):433-40 [8188285.001]
  • [Cites] Semin Diagn Pathol. 1995 Aug;12(3):233-48 [8545590.001]
  • [Cites] Gen Diagn Pathol. 1996 May;141(5-6):327-37 [8780932.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1322-6 [8918447.001]
  • [Cites] Histopathology. 1996 Dec;29(6):507-16 [8971557.001]
  • [Cites] Neuroradiology. 1997 Oct;39(10):719-23 [9351109.001]
  • [Cites] Am J Clin Pathol. 1990 Nov;94(5):645-8 [1700599.001]
  • (PMID = 20065575.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC3023103
  •  go-up   go-down


37. Kim TY, Jin CY, Kim GY, Choi IW, Jeong YK, Nam TJ, Kim SK, Choi YH: Ethyl alcohol extracts of Hizikia fusiforme sensitize AGS human gastric adenocarcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis. J Med Food; 2009 Aug;12(4):782-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethyl alcohol extracts of Hizikia fusiforme sensitize AGS human gastric adenocarcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis.
  • Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis has been reported in some cancer cells, including AGS human gastric adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Apoptosis / drug effects. Phaeophyta. Plant Extracts / therapeutic use. Stomach Neoplasms / drug therapy. TNF-Related Apoptosis-Inducing Ligand / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19735177.001).
  • [ISSN] 1557-7600
  • [Journal-full-title] Journal of medicinal food
  • [ISO-abbreviation] J Med Food
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Chromatin; 0 / Ligands; 0 / Plant Extracts; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / bcl-2-Associated X Protein; 9007-49-2 / DNA; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspases
  •  go-up   go-down


38. Giglio P, Weinberg JS, Forman AD, Wolff R, Groves MD: Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract. Cancer; 2005 Jun 1;103(11):2355-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract.
  • RESULTS: The patient population was composed of patients with gastric adenocarcinoma (n = 8 patients), esophageal adenocarcinoma (n = 7 patients), colon and/or rectal adenocarcinoma (n = 5 patients), and pancreatic adenocarcinoma (n = 1 patient).
  • The median overall survival after the initial diagnosis of adenocarcinoma was 55 weeks (range, 8-884 wks), and the median survival after the diagnosis of NM was 7 weeks (range, 0-64 wks).
  • No factors identified had an impact on outcome, including symptoms, physical findings at diagnosis, imaging characteristics, or cerebrospinal fluid findings.
  • CONCLUSIONS: Patients with NM from GI tract adenocarcinomas universally had poor outcomes.
  • [MeSH-major] Adenocarcinoma / secondary. Gastrointestinal Neoplasms / pathology. Meningeal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15856426.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


39. Wilson KT, Crabtree JE: Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology; 2007 Jul;133(1):288-308
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori infects the stomach of half of the human population worldwide and causes chronic active gastritis, which can lead to peptic ulcer disease, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma.

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631150.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK058404; United States / NIDDK NIH HHS / DK / R01 DK053620; United States / NIDDK NIH HHS / DK / R21 DK063626; United States / NIDDK NIH HHS / DK / R41 DK075161
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Vaccines
  • [Number-of-references] 253
  •  go-up   go-down


40. Bao H, Boussioutas A, Reynolds J, Russell S, Gu M: Imaging of goblet cells as a marker for intestinal metaplasia of the stomach by one-photon and two-photon fluorescence endomicroscopy. J Biomed Opt; 2009 Nov-Dec;14(6):064031
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of goblet cells as a marker for intestinal metaplasia of the stomach by one-photon and two-photon fluorescence endomicroscopy.
  • Goblet cells are a requirement for the diagnosis of intestinal metaplasia of the stomach.
  • The gastric mucosa is lined by a monolayer of columnar epithelium with some specialization at the crypts, but there are no goblet cells in normal gastric epithelium.
  • The appearance of goblet cells in gastric epithelium is an indicator of potential malignant progression toward adenocarcinoma.
  • Therefore, in vivo three-dimensional imaging of goblet cells is essential for diagnoses of a premalignant stage of gastric cancers called intestinal metaplasia.
  • These results prove that two-photon fluorescence endomicroscopy is advantageous in diagnoses of a premalignant stage of gastric cancers.
  • [MeSH-minor] Animals. Fluorescein. Imaging, Three-Dimensional / methods. Metaplasia / pathology. Mice. Precancerous Conditions / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUORESCEIN .
  • Hazardous Substances Data Bank. D&C Yellow No. 8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20059269.001).
  • [ISSN] 1560-2281
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] TPY09G7XIR / Fluorescein
  •  go-up   go-down


41. Zhan YQ, Sun XW, Li W, Chen YB, Xu L, Guan YX, Li YF, Xu DZ: [Multivariate prognostic analysis in gastric carcinoma patients after radical operation]. Ai Zheng; 2005 May;24(5):596-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate prognostic analysis in gastric carcinoma patients after radical operation].
  • BACKGROUND & OBJECTIVE: Whether received radical operation is an important prognostic factor of gastric carcinoma.
  • This study was to investigate prognostic factors of gastric carcinoma.
  • METHODS: Clinical data of 405 patients with gastric carcinoma, received radical operation from Jan.
  • 1985 to Dec. 1995 in Cancer Center of Sun Yat-sen University, were analyzed retrospectively.
  • Univariate analysis showed that perioperative chemotherapy, Borrmann type, tumor size, pathologic type, and pTNM stage were prognostic factors of gastric carcinoma.
  • Multivariate analysis showed that pTNM stage, tumor size, and perioperative chemotherapy were independent prognostic factors of gastric carcinoma.
  • CONCLUSIONS: pTNM stage, tumor size, and perioperative chemotherapy are the most significant factors influencing prognosis of gastric carcinoma patients after radical operation.
  • Perioperative chemotherapy contributes to enhance survival rate of gastric carcinoma patients.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / surgery. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Life Tables. Male. Middle Aged. Neoplasm Staging. Perioperative Care. Prognosis. Proportional Hazards Models. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890105.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


42. Lee HJ, Kim SW, Kim HY, Li S, Yun HJ, Song KS, Kim S, Jo DY: Chemokine receptor CXCR4 expression, function, and clinical implications in gastric cancer. Int J Oncol; 2009 Feb;34(2):473-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptor CXCR4 expression, function, and clinical implications in gastric cancer.
  • The chemokine receptor CXCR4 is associated with the biological behavior of cancer, but few studies have addressed the expression and function of CXCR4 in human gastric cancer and its impact on disease prognosis.
  • We studied the expression of CXCR4 using RT-PCR, Western blotting, flow cytometry, and confocal microscopy in five gastric cancer cell lines.
  • Furthermore, we investigated the correlation between CXCR4 expression and the clinical features of 221 gastric cancer tissue samples.
  • CXCR4 transcripts and proteins were detectable in all five gastric cancer cell lines.
  • Gastric cancer tissue samples expressed CXCR4 with variable intensities.
  • In conclusion, CXCR4 expression is associated with gastric cancer cell migration in vitro, and strong expression of CXCR4 by gastric cancer cells is significantly associated with lymphatic metastasis in patients with gastric cancer, suggesting that CXCR4 plays an important role during gastric cancer progression.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Receptors, CXCR4 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma / physiopathology. Aged. Blotting, Western. Cell Division. Cell Line, Tumor. DNA Primers. Disease Progression. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Male. Middle Aged. Multiple Myeloma / genetics. Neoplasm Invasiveness. Neoplasm Staging. Signal Transduction. Tumor Cells, Cultured


43. Seshimo K, Tanaka N, Yamashita Y, Oishi M, Kodera M, Yamamura M, Katoh H, Ikeda H, Yokomichi N, Toshima T, Kawai Y, Shibagaki K, Maejima R, Fujita H, Ichimura K, Takita K: [A case of early poorly-differentiated neuroendocrine carcinoma of stomach]. Gan To Kagaku Ryoho; 2010 Feb;37(2):319-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of early poorly-differentiated neuroendocrine carcinoma of stomach].
  • Gastric endoscopy showed a type IIa+IIc tumor at the anterior wall of the gastric angle.
  • Based on the pathology of the biopsy specimen, poorly-differentiated adenocarcinoma was diagnosed.
  • The tumor was diagnosed as poorly-differentiated neuroendocrine carcinoma of the stomach.
  • Neuroendocrine cell carcinoma of the stomach is rare and usually has a very poor prognosis.
  • Thus, we are reporting this case of early poorly-differentiated neuroendocrine carcinoma of the stomach that was curatively resected and had 12-month survival without recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinoma, Neuroendocrine / pathology. Cell Differentiation. Oxonic Acid / therapeutic use. Stomach Neoplasms / pathology. Tegafur / therapeutic use

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154494.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


44. Rocco A, Pomponi D, Borriello P, D'Armiento F, Nardone G: An unusual case of high alpha-fetoprotein level and liver masses. Dig Liver Dis; 2008 Mar;40(3):224
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / blood. Liver Neoplasms / blood. Stomach Neoplasms / blood
  • [MeSH-minor] Biopsy. Carcinoma, Hepatocellular / diagnosis. Diagnosis, Differential. Fatal Outcome. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096450.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


45. Tamizi-Far B, Taghavi A, Rismankar-Zadeh M: An unusual cause of thrombotic thrombocytopenic purpura in pregnancy. Arch Iran Med; 2007 Jul;10(3):390-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although most cases are assumed to be idiopathic, its association with malignancy is well-recognized and it usually occurs at the terminal stage of cancer.
  • It is generally idiopathic, and its association with adenocarcinomas is extremely rare.
  • [MeSH-major] Adenocarcinoma / secondary. Pregnancy Complications, Hematologic / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Purpura, Thrombotic Thrombocytopenic / diagnosis. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17604481.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


46. Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, Clemons NJ, Hardwick JS, Zhang C, Das M, Save V, Novelli M, Balkwill F, Fitzgerald RC: Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A; 2010 Feb 02;107(5):2177-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stromal compartment is increasingly recognized to play a role in cancer.
  • Supervised clustering of gene expression profiles from microdissected stroma identified a gene signature that could distinguish between BE metaplasia, dysplasia, and esophageal adenocarcinoma (EAC).
  • Gene set enrichment analysis of external datasets demonstrated that the stromal signature was also relevant in the preinvasive to invasive transition of the stomach, colon, and pancreas.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / immunology. Adenocarcinoma / pathology. Barrett Esophagus / genetics. Barrett Esophagus / immunology. Barrett Esophagus / pathology. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Cytokines / genetics. DNA-Binding Proteins / genetics. Esophageal Neoplasms / genetics. Esophageal Neoplasms / immunology. Esophageal Neoplasms / pathology. Gelatinases / genetics. Humans. Inflammation / genetics. Inflammation / immunology. Inflammation / pathology. Membrane Proteins / genetics. Metaplasia. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Nuclear Proteins / genetics. Oncogenes. Precancerous Conditions / genetics. Precancerous Conditions / immunology. Precancerous Conditions / pathology. Prognosis. Proto-Oncogene Proteins c-bcl-6. Receptors, Cytokine / genetics. Serine Endopeptidases / genetics. Stromal Cells / immunology. Stromal Cells / pathology. Trans-Activators / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Carcinogenesis. 2009 Jul;30(7):1073-81 [19468060.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5358-64 [12235007.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2569-77 [12750281.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2649-57 [12750293.001]
  • [Cites] Cell. 2004 Aug 6;118(3):285-96 [15294155.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7629-33 [15492292.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9215-9 [1409627.001]
  • [Cites] Oncogene. 1999 Jan 14;18(2):467-75 [9927203.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Nature. 2004 Dec 2;432(7017):635-9 [15577913.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jan;3(1):1-10 [15645398.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3146-54 [15833844.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11005-10 [16043716.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):201-8 [16188230.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6626-36 [16103885.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Gut. 2006 Jun;55(6):764-74 [16368780.001]
  • [Cites] Oncogene. 2006 Jun 1;25(23):3346-56 [16449976.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):925-33 [16952561.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65 [17255290.001]
  • [Cites] PLoS One. 2007;2(1):e177 [17264880.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3356-65 [17921324.001]
  • [Cites] Mol Cancer Res. 2007 Dec;5(12):1263-75 [18171984.001]
  • [Cites] Science. 2008 Apr 4;320(5872):38-41 [18388269.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):926-31 [18192685.001]
  • [Cites] Prostate. 2008 Sep 1;68(12):1362-71 [18512730.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • [Cites] Nat Cell Biol. 2009 Apr;11(4):451-9 [19287377.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):501-7 [19410194.001]
  • [Cites] Breast Cancer Res. 2009;11(1):R7 [19187537.001]
  • [Cites] Gut. 2002 Apr;50(4):451-9 [11889061.001]
  • (PMID = 20080664.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE19529/ GSE19632
  • [Grant] United Kingdom / Medical Research Council / / G0501974; United Kingdom / Medical Research Council / / MC/ U105365007; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Cytokines; 0 / DNA-Binding Proteins; 0 / JMY protein, human; 0 / Membrane Proteins; 0 / Nuclear Proteins; 0 / PMEPA1 protein, human; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Receptors, Cytokine; 0 / SPZ1 protein, human; 0 / Trans-Activators; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  • [Other-IDs] NLM/ PMC2836667
  •  go-up   go-down


47. Yoshikawa T, Omura K, Kobayashi O, Nashimoto A, Takabayashi A, Yamada T, Yamaue H, Fujii M, Yamaguchi T, Nakajima T: A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). Eur J Surg Oncol; 2010 Jun;36(6):546-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study).
  • AIMS: Clinically serosa-positive (T3-4) gastric cancer has a poor prognosis.
  • This phase II trial explored the feasibility and safety of preoperative chemotherapy followed by D2 or D3 gastrectomy in this type of gastric cancer.
  • METHODS: Patients with T3-4 gastric cancer received one course of S-1 (80mg/m(2) daily for 3 weeks) and cisplatin (60mg/m(2) on day 8) chemotherapy and then underwent D2 or D3 gastrectomy with curative intent.
  • CONCLUSION: This multi-modality treatment seems to be feasible and safe for T3-4 gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy / methods. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20541062.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


48. Liu X, Hua BJ: [Effect of traditional Chinese medicine on quality of life and survival period in patients with progressive gastric cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Feb;28(2):105-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of traditional Chinese medicine on quality of life and survival period in patients with progressive gastric cancer].
  • OBJECTIVE: To investigate the effect of traditional Chinese medicine (TCM) on quality of life (QOF) and survival period in patients with progressive gastric cancer, and thus exploring its clinical efficacy.
  • METHODS: TCM therapy applied in the 34 patients assigned in the TCM group (Group I ) included intravenous injection of Cinobufotalin, beta-elemene, or orally taking of anti-cancer Chinese herbs.
  • CONCLUSION: Chinese medicine treatment can improve the QOF and prolong the survival period of patients with progressive gastric cancer with few side effects.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386568.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Bufanolides; 0 / Drugs, Chinese Herbal; 0 / Sesquiterpenes; 0 / beta-elemene; 1108-68-5 / cinobufotalin
  •  go-up   go-down


49. Osumi W, Fujita Y, Hiramatsu M, Kawai M, Sumiyoshi K, Umegaki E, Tokioka S, Yoda Y, Egashira Y, Abe S, Higuchi K, Tanigawa N: Endoscopic submucosal dissection allows less-invasive curative resection for gastric tube cancer after esophagectomy - a case series. Endoscopy; 2009 Sep;41(9):777-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic submucosal dissection allows less-invasive curative resection for gastric tube cancer after esophagectomy - a case series.
  • Detection of early gastric tube cancers (GTCs) has increased with more detailed surveillance endoscopy using indigo carmine dye following esophagectomy.
  • Overall, eight GTCs were identified in seven (6.3 %) of 112 patients who underwent esophagectomy and gastric tube reconstruction.
  • [MeSH-major] Esophageal Neoplasms / pathology. Esophagostomy / methods. Gastrostomy / methods. Neoplasms, Squamous Cell / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma, Papillary / pathology. Aged. Aged, 80 and over. Coloring Agents. Dissection / methods. Endoscopy, Gastrointestinal. Esophagectomy. Female. Gastrectomy. Gastric Mucosa / pathology. Humans. Indigo Carmine. Middle Aged. Reconstructive Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. INDIGO .
  • Hazardous Substances Data Bank. Indigotindisulfonate sodium .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19746318.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Coloring Agents; D3741U8K7L / Indigo Carmine
  •  go-up   go-down


50. Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM: Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann Surg Oncol; 2007 Oct;14(10):2721-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma.
  • OBJECTIVE: We had previously demonstrated that human leukocyte antigen G (HLA-G) was expressed in a majority of primary colorectal carcinomas and that the detection of HLA-G expression had a strong and independent prognostic value for that cancer.
  • Currently, we investigate whether or not HLA-G is also expressed in patients with gastric carcinoma and whether the expression has any clinical application value.
  • METHODS: The expression of HLA-G was investigated immunohistochemically in 160 patients with gastric carcinoma.
  • RESULTS: HLA-G protein expression was observed in 71% (113 of 160) of the primary site of gastric carcinomas, but not in the normal stomach tissues.
  • CONCLUSIONS: Overall, our results indicated that the expression of HLA-G is a characteristic feature of gastric carcinoma and that immunostaining by anti-HLA-G antibody may be a potentially useful prognostic indicator.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Carcinoma, Adenosquamous / pathology. Carcinoma, Signet Ring Cell / pathology. HLA Antigens / analysis. Histocompatibility Antigens Class I / analysis. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Gastrectomy. HLA-G Antigens. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Pregnancy. Prognosis. Statistics as Topic. Stomach / pathology. Survival Rate. Trophoblasts / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17564748.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


51. Hur H, Kim JY, Cho YK, Han SU: Technical feasibility of robot-sewn anastomosis in robotic surgery for gastric cancer. J Laparoendosc Adv Surg Tech A; 2010 Oct;20(8):693-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Technical feasibility of robot-sewn anastomosis in robotic surgery for gastric cancer.
  • BACKGROUND: Although several studies have reported on the feasibility of robot-assisted gastric cancer surgery using the da Vinci surgical system, reconstruction techniques have depended on staplers or hand sewing through minilaparotomy.
  • AIM: The aim of this study is to report on the feasibility of reconstruction methods using a robot-sewing technique in robotic surgery for treatment of gastric cancer.
  • PATIENT AND METHODS: Between January and April 2010, 7 patients in whom gastric adenocarcinoma was diagnosed underwent robotic surgery including robot-sewn anastomosis.
  • One patient was readmitted for stasis in the remnant stomach but conservatively recovered.
  • CONCLUSIONS: A robot-sewn anastomosis for reconstruction in robotic surgery for gastric cancer was feasible regardless of the reconstruction method.
  • [MeSH-major] Adenocarcinoma / surgery. Anastomosis, Surgical / methods. Robotics. Stomach Neoplasms / surgery. Suture Techniques

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20809816.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Ueda J, Aimoto T, Nakamura Y, Hiroi M, Yamahatsu K, Hayakawa T, Naito Z, Uchida E: [Pancreaticoduodenal lymph node metastasis of neuroendocrine carcinoma of unknown primary associated with duodenal carcinoma]. Nihon Shokakibyo Gakkai Zasshi; 2010 12;107(12):1941-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although as duodenal GIST was diagnosed, histologic examination for frozen sections during the procedure revealed tubular adenocarcinoma of the duodenum and pancreaticoduodenal lymph node metastasis of neuroendocrine carcinoma.
  • He underwent a subtotal stomach-preserving pancreaticoduodenectomy.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Neuroendocrine / secondary. Duodenal Neoplasms / pathology. Neoplasms, Unknown Primary

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139363.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


53. Yao HL, Yang ZL, Li YG: [Expression and significance of prostate stem cell antigen and Oct-4 in benign and malignant lesions of the stomach]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul;33(7):623-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of prostate stem cell antigen and Oct-4 in benign and malignant lesions of the stomach].
  • OBJECTIVE: To determine on the expression of prostate stem cell antigen (PCSA )and Oct-4 and detect their clinicopathological significance in benign and malignant lesions of the stomach.
  • METHODS: EnVision immunohistochemistry for assaying the expression of PSCA and Oct-4 was used in paraffin-embedded sections from specimens of primary foci (n = 58) and metastatic foci of regional lymph nodes (n = 36) of gastric cancer, peritumoral tissues (n = 20), and benign lesions of the stomach (n = 80).
  • RESULTS: The positive rates of PSCA and Oct-4 were significantly higher in gastric cancer than those in peritumoral tissues and benign lesions (P<0.05 or P<0.01).The positive cases of PSCA and Oct-4 in peritumoral tissues and benign lesions showed mild- to severe-atypical hyperplasia.
  • No difference of the positive rate of PSCA and Oct-4 was found between the primary foci and the metastatic foci of gastric cancer(P > 0.05).
  • The positive rates of PSCA and Oct-4 were significantly lower in infiltrating depth T(1) to approximately T(2), non-metastasis of lymph nodes, metastasis of lymph nodes N1 site, and non-metastasis of distant organs than those in infiltrating depth T(3) to approximately T(4), metastasis of lymph nodes, metastasis of lymph node N(2) to approximately N(3) site, and metastasis of distant organs(P < 0.05 or P < 0.01).Conclusion The expressive levels of PSCA and Oct-4 might be related to the invasive potential, metastasis of lymph nodes, and distant organs, it suggested the expressions levels of PSCA and Oct-4 might be important markers for reflecting the biological behaviors and prognosis of gastric cancer.
  • [MeSH-major] Biomarkers, Tumor. Membrane Glycoproteins / biosynthesis. Neoplasm Proteins / biosynthesis. Octamer Transcription Factor-3 / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Antigens, Neoplasm. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18667777.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-3; 0 / PSCA protein, human
  •  go-up   go-down


54. Mao J, Xu Z, Fang Y, Wang H, Xu J, Ye J, Zheng S, Zhu Y: Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci; 2008 Nov;99(11):2120-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation.
  • Hepatoma-derived growth factor (HDGF) is related to tumorigenesis and the development of cancer; it is an independent factor associated with the prognosis of liver cancer, non-small cell lung cancer and pancreatic cancer.
  • However, the molecular mechanism by which HDGF participates in gastric carcinogenesis and development as well as its functional regulation during the development of gastric precancerous lesions needs to be further analyzed.
  • In the present study, we analyzed the effect of HDGF transfection on the proliferation and on the changes of mitogen-activated protein kinase (MAPK), Akt, and nuclear factor-kB (NF-kB) pathways in gastric cancer AGS cells.
  • Further studies showed that HDGF expression gradually increased in the gastric carcinogenesis process and HDGF showed a high expression in poorly differentiated adenocarcinoma prone to lymphoid metastasis; these findings suggest that HDGF is involved in the gastric carcinogenesis process and promotes proliferation and metastasis via Erk1/2 activation.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Gastric Mucosa / enzymology. Intercellular Signaling Peptides and Proteins / metabolism. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Stomach Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / metabolism. Cell Line, Tumor. Cell Proliferation. Epithelial Cells / cytology. Epithelial Cells / metabolism. Humans. NF-kappa B / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Transfection

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18823380.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / NF-kappa B; 0 / hepatoma-derived growth factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


55. Marques ML, D'Alessandro GS, Chade DC, Lanzoni VP, Saiovici S, Almeida CJ: Primary mucinous adenocarcinoma of the bladder with signet-ring cells: case report. Sao Paulo Med J; 2007 Sep 6;125(5):297-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucinous adenocarcinoma of the bladder with signet-ring cells: case report.
  • CONTEXT: Primary adenocarcinomas of the bladder are uncommon and usually occur by contiguity with or hematogenic dissemination of other adenocarcinomas such as colorectal, prostate and gynecological tract carcinomas.
  • Mucinous and signet-ring cell histological patterns are even rarer and it is often difficult to morphologically distinguish them from metastatic colorectal adenocarcinoma.
  • CASE REPORT: We present and discuss a rare case of primary mucinous adenocarcinoma of the bladder with signet-ring cells in a 57-year-old male patient.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Signet Ring Cell / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Humans. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Mucin-2. Mucins / analysis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094900.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


56. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, Cavazzini L, Volinia S, Alder H, Ruco LP, Baldassarre G, Croce CM, Vecchione A: E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell; 2008 Mar;13(3):272-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer.
  • Deregulation of E2F1 activity and resistance to TGFbeta are hallmarks of gastric cancer.
  • Here we provide evidence that the miR-106b-25 cluster, upregulated in a subset of human gastric tumors, is activated by E2F1 in parallel with its host gene, Mcm7.
  • Together, these results suggest that the miR-106b-25 cluster is involved in E2F1 posttranscriptional regulation and may play a key role in the development of TGFbeta resistance in gastric cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Apoptosis / genetics. Cell Cycle / genetics. E2F1 Transcription Factor / metabolism. Gene Expression Regulation, Neoplastic. MicroRNAs / metabolism. RNA Processing, Post-Transcriptional. Stomach Neoplasms / genetics. Transforming Growth Factor beta / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18328430.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] Italy / Telethon / / GTF03012
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BCL2L11 protein, human; 0 / Bcl-2-Like Protein 11; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / E2F1 Transcription Factor; 0 / E2F1 protein, human; 0 / Membrane Proteins; 0 / MicroRNAs; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta; EC 3.6.4.12 / MCM7 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 7
  •  go-up   go-down


57. Xu JD, Furuya T, Cao XX, Liu XL, Li QQ, Wang WJ, Xu JW, Xu ZD, Sasaki K, Liu XP: Loss of BCL2L10 protein expression as prognostic predictor for poor clinical outcome in gastric carcinoma. Histopathology; 2010 Dec;57(6):814-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of BCL2L10 protein expression as prognostic predictor for poor clinical outcome in gastric carcinoma.
  • The clinical significance of its expression in gastric carcinoma is poorly understood.
  • The aim was to investigate BCL2L10 expression and its clinical and prognostic significance in gastric carcinoma patients.
  • METHODS AND RESULTS: Immunohistochemistry, real-time polymerase chain reaction (PCR) and immunoblotting all revealed extensive loss of BCL2L10 expression in gastric cancer cells.
  • Multivariate regression analysis showed that loss of BCL2L10 protein expression [P=4.883×10(-8), hazard ratio (HR)=0.252] is an independent prognostic predictor of gastric carcinoma.
  • The receiver operator characteristic (ROC) curve showed that the area for BCL2L10 protein was 0.817 (P=8.331×10(-14)), indicating that loss of BCL2L10 protein expression is an excellent prognostic predictor of gastric carcinoma.
  • CONCLUSIONS: Loss of BCL2L10 protein expression predicts poor clinical outcome in gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Limited.
  • (PMID = 21166696.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL2-like 10 protein; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger
  •  go-up   go-down


58. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, Nagahori Y, Takahashi M, Kito F, Shimada H: Clinicopathological properties of poorly-differentiated adenocarcinoma of the stomach: comparison of solid- and non-solid-types. Anticancer Res; 2006 Jan-Feb;26(1B):639-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological properties of poorly-differentiated adenocarcinoma of the stomach: comparison of solid- and non-solid-types.
  • BACKGROUND: The purpose of this study was to clarify the clinicopathological and biological properties of the poorly-differentiated types of gastric carcinoma (solid-type and non-solid-type).
  • PATIENTS AND METHODS: A total of 1,558 patients with primary gastric adenocarcinomas were enrolled in this study.
  • CONCLUSION: Therapeutic strategies should be based on the histological type of the tumor in patients with poorly-differentiated gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16739333.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


59. Kiyotoki S, Nishikawa J, Yanai H, Okamoto T, Higaki S, Taguchi T, Sakaida I: Use of the light-emitting diode-illuminated endoscope for upper gastrointestinal endoscopy. Endoscopy; 2009;41 Suppl 2:E173-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endoscopes, Gastrointestinal. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19629942.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


60. Yamamura Y, Ito S, Mochizuki Y, Nakanishi H, Tatematsu M, Kodera Y: Distribution of free cancer cells in the abdominal cavity suggests limitations of bursectomy as an essential component of radical surgery for gastric carcinoma. Gastric Cancer; 2007;10(1):24-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of free cancer cells in the abdominal cavity suggests limitations of bursectomy as an essential component of radical surgery for gastric carcinoma.
  • BACKGROUND: Bursectomy, which has been performed so as to resect peritoneal deposits disseminated within the omental bursa, is considered as an essential component of radical surgery for gastric carcinoma in Japan.
  • Bursectomy has also been described in the Japanese Treatment Guidelines for Gastric Carcinoma as a mandatory procedure for the treatment of serosa-positive cancer.
  • METHODS: Cytologic examination and real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of the peritoneal washes obtained from the Douglas pouch, left subphrenic cavity, and inside the omental bursa were performed for 136 patients who underwent potentially curative surgery for gastric carcinoma.
  • CONCLUSION: It is unlikely that viable cancer cells disseminated into the bursa remain restricted to this cavity without migrating into the free abdominal cavity.
  • Routine bursectomy may not be an essential procedure for resecting gastric cancer, from the viewpoint of eliminating microscopic peritoneal deposits within the omental bursa.
  • [MeSH-major] Adenocarcinoma / surgery. Neoplasm Seeding. Peritoneal Neoplasms / surgery. Peritoneum / cytology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2004 Jan;11(1):14-20 [14699028.001]
  • [Cites] J Am Coll Surg. 2006 Feb;202(2):231-6 [16427547.001]
  • [Cites] Ann Surg Oncol. 1997 Apr-May;4(3):209-14 [9142381.001]
  • [Cites] Jpn J Cancer Res. 1997 Jul;88(7):687-92 [9310142.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):130-6 [8318403.001]
  • [Cites] World J Gastroenterol. 2006 Mar 7;12(9):1408-11 [16552810.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):687-92 [8425204.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 23;313(4):931-7 [14706632.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):411-7 [11008202.001]
  • [Cites] Br J Surg. 2004 Apr;91(4):435-43 [15048743.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):637-44 [16077911.001]
  • [Cites] Gastric Cancer. 2005;8(3):142-8 [16086116.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):986-92 [16205696.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Gastric Cancer. 2002;5(2):69-76 [12111581.001]
  • [Cites] Am J Gastroenterol. 1996 Jan;91(1):49-53 [8561143.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):429-33 [9699538.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):499-506 [11923605.001]
  • (PMID = 17334714.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-20; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


61. Costantini R, De Nicola P, Bianco F, Cotroneo AR, Iezzi R, Di Bartolomeo N, Innocenti P: Tumor vs non-tumor origin of occult and obscure gastrointestinal bleeding requiring hospitalization. Tumori; 2007 Sep-Oct;93(5):461-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Thirty-five cases of obscure and 27 cases of occult bleeding were examined; all received a definite diagnosis during hospitalization.
  • In the cases with obscure bleeding the diagnosis was inflammatory bowel disease (n = 7), angiodysplasia (5 gastric, 2 duodenal, 2 jejunal, 3 ileal, 4 right colon), small bowel tumors (4 non-Hodgkin lymphomas, 1 leiomyoma, 6 adenocarcinomas), and gastric metaplasia of Meckel's diverticulum (n = 1).
  • Intestinal resections were performed for all small bowel tumors (8 laparotomic, 3 laparoscopic), 5 angiodysplasias, all cases of inflammatory bowel disease and gastric metaplasia of Meckel's diverticulum; arterial embolization was performed for 11 angiodysplasias.
  • In the cases with occult bleeding the diagnosis was sigmoid colon polyps in 6 (treatment, endoscopic polypectomy) and right colon cancer in 21 (treatment, right hemicolectomy).
  • Thanks to modern technology, however, their diagnosis and treatment can nowadays be promptly and successfully achieved.
  • [MeSH-major] Gastrointestinal Hemorrhage / diagnosis. Intestinal Neoplasms / diagnosis. Occult Blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Capsules. Diagnosis, Differential. Endoscopy, Gastrointestinal. Female. Follow-Up Studies. Humans. Intestine, Small / pathology. Male. Middle Aged. Treatment Outcome. Videotape Recording

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038878.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Capsules
  •  go-up   go-down


62. Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, Izbicki JR, Sauter G: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol; 2009 Jun;40(6):769-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER-2 amplification is highly homogenous in gastric cancer.
  • Her-2 is the molecular target for antibody-based treatment of breast cancer (trastuzumab).
  • The potential benefit of anti-Her-2 therapy is currently investigated in several other HER-2-amplified cancers including gastric cancer.
  • Although HER-2 amplification occurs in more than 10% of gastric cancers, potential heterogeneity of HER-2 amplification and overexpression could represent a major drawback for anti-Her-2 therapy.
  • To address the potential applicability of trastuzumab in gastric cancer, tissue microarray sections of 166 gastric adenocarcinomas and 69 lymph node metastases were analyzed for Her-2 overexpression and amplification using Food and Drug Administration-approved reagents for immunohistochemistry and fluorescence in situ hybridization.
  • HER-2 amplification was seen in 27 (16%) of 166 gastric adenocarcinomas.
  • Moreover, HER-2 and Topoisomerase IIalpha coamplification analysis of 3 to 16 large sections from 8 Her-2-positive gastric cancers did not reveal any heterogeneity of the amplicon site.
  • The high level of HER-2 amplification in combination with the homogeneity of its expression in primary and metastatic tumors argues for a possible therapeutic utility of trastuzumab in HER-2-amplified gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2 / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2011 Jun;42(6):909-10; author reply 910-1 [21571126.001]
  • [CommentIn] Hum Pathol. 2010 Feb;41(2):304-5; author reply 305-6 [19914678.001]
  • (PMID = 19269014.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; P188ANX8CK / Trastuzumab
  •  go-up   go-down


63. Sasaki T, Koizumi W, Higuchi K, Ishido K, Ae T, Nakatani K, Katada C, Tanabe S, Saigenji K: [Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint]. Gan To Kagaku Ryoho; 2007 Jul;34(7):988-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint].
  • Type 4 gastric cancer has a poor prognosis compared with other types of advanced gastric cancer because of the high incidence of peritoneal metastasis which causes intestinal obstruction, hydronephrosis, or obstructive jaundice.
  • S-1 showed a higher response rate for undifferentiated-type adenocarcinoma, and S-1 alone or its combination regimens demonstrated greater anti-tumor effects and longer survival time for gastric linitis plastica compared with conventional 5-FU regimens in our historical control study (response rate: S-1/non S-1 57.9%/27.9%, p<0.01; MST: S-1/non S-1 402 days/213 days, p<0.01).
  • S-1 regimens may also improve the survival in patients with type 4 gastric cancer in neoadjuvant or adjuvant settings, but further prospective studies are warranted to prove its significance.
  • Paclitaxel also has a high response rate for undifferentiated-type adenocarcinoma, and can be expected to show high efficacy for peritoneal dissemination.
  • However,survival of patients with type 4 gastric cancer may improve with the availability of active agents like S-1, taxanes, irinotecan as reported in colorectal cancer.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637532.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


64. Jensen EH, Tuttle TM: Preoperative staging and postoperative surveillance for gastric cancer. Surg Oncol Clin N Am; 2007 Apr;16(2):329-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative staging and postoperative surveillance for gastric cancer.
  • Physicians must consider multiple factors when determining the most appropriate preoperative imaging strategy for gastric cancer.
  • Based on the reviewed literature, we do not recommend routine surveillance imaging after curative surgery for gastric cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Neoplasm Staging. Postoperative Care / methods. Preoperative Care / methods. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560516.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


65. Takasu S, Tsukamoto T, Ushijima T, Yamashita S, Ogasawara N, Ban H, Yanai T, Masegi T, Tatematsu M: Cyclin D1 overexpression in N-methyl-N'-nitro-N-nitrosoguanidine-induced rat gastric adenocarcinomas. Exp Toxicol Pathol; 2007 Nov;59(3-4):171-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D1 overexpression in N-methyl-N'-nitro-N-nitrosoguanidine-induced rat gastric adenocarcinomas.
  • Changes in cell cycle regulation are involved in many human cancers, including gastric cancer.
  • In the present study, cyclin D1 expression and localization were immunohistochemically analyzed in 23 N-methyl-N'-nitro-N-nitrosoguanidine-induced rat gastric adenocarcinomas and compared with findings for beta-catenin.
  • Cyclin D1 was also found to be accumulated in gastric glands within normal-looking mucosa, these perhaps representing preneoplastic lesions for cancers with membranous beta-catenin accumulation.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinogens / toxicity. Cyclins / metabolism. Methylnitronitrosoguanidine / toxicity. Stomach Neoplasms / metabolism
  • [MeSH-minor] Animals. Cell Membrane / drug effects. Cell Membrane / metabolism. Cell Membrane / pathology. Cell Nucleus / drug effects. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cyclin D. Cytoplasm / drug effects. Cytoplasm / metabolism. Cytoplasm / pathology. Gastric Mucosa / drug effects. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Immunohistochemistry. Male. Rats. Rats, Inbred ACI. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. N-METHYL-N'-NITRO-N-NITROSOGUANIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17855062.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Ctnnb1 protein, rat; 0 / Cyclin D; 0 / Cyclins; 0 / beta Catenin; 12H3O2UGSF / Methylnitronitrosoguanidine
  •  go-up   go-down


66. Vallot T: [Gastric polyps]. Presse Med; 2007 Oct;36(10 Pt 2):1412-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric polyps].
  • Gastric polyps exist in a wide variety of types, most often benign.
  • Endoscopic discovery of gastric polyps necessitates biopsies - not only of the lesion but also of the antral and fundic mucosa to determine the therapeutic strategy and subsequent surveillance.
  • These polyps are associated with an elevated frequency of precancerous alterations of the gastric mucosa and consequently by an elevated risk of synchronous or metachronous cancer.
  • Eradication of Helicobacter pylorus may reduce the risk of metachronous gastric cancer and recurrence after resection.
  • The advantages and procedures for endoscopic surveillance of patients with a precancerous condition of the gastric mucosa have not yet been clearly established in populations with a low incidence of cancer.
  • [MeSH-major] Adenocarcinoma. Adenoma. Carcinoid Tumor. Polyps. Precancerous Conditions. Stomach Diseases. Stomach Neoplasms
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Endoscopy. Helicobacter Infections / complications. Helicobacter Infections / prevention & control. Helicobacter pylori. Humans. Incidence. Lymphatic Metastasis. Neoplasm Metastasis. Prevalence. Risk Factors. Stomach / pathology

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17482791.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 35
  •  go-up   go-down


67. Mizoshita T, Tsukamoto T, Inada KI, Hirano N, Tajika M, Nakamura T, Ban H, Tatematsu M: Loss of MUC2 expression correlates with progression along the adenoma-carcinoma sequence pathway as well as de novo carcinogenesis in the colon. Histol Histopathol; 2007 03;22(3):251-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of MUC2 expression correlates with progression along the adenoma-carcinoma sequence pathway as well as de novo carcinogenesis in the colon.
  • AIMS: We have previously demonstrated links between clinicopathological findings and phenotypes using several gastric and intestinal phenotypic markers in stomach and pancreatic cancers.
  • METHODS AND RESULTS: We examined the correlation between gastric and intestinal phenotypic expression in 91 primary early carcinomas of the colon.
  • Intramucosal de novo carcinomas (flat type carcinomas without adenomatous components) exhibited a greater decrease of MUC2 than intramucosal lesions with adenomatous components.
  • CONCLUSIONS: Our data suggest that the reduction of MUC2 expression may be associated with the occurrence and progression of colorectal carcinomas in both adenoma-carcinoma sequence pathway and de novo carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Villous / metabolism. Colorectal Neoplasms / metabolism. Mucins / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163399.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC6 protein, human; 0 / Microfilament Proteins; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucin-6; 0 / Mucins; 0 / villin
  •  go-up   go-down


68. Gomes LI, Esteves GH, Carvalho AF, Cristo EB, Hirata R Jr, Martins WK, Marques SM, Camargo LP, Brentani H, Pelosof A, Zitron C, Sallum RA, Montagnini A, Soares FA, Neves EJ, Reis LF: Expression profile of malignant and nonmalignant lesions of esophagus and stomach: differential activity of functional modules related to inflammation and lipid metabolism. Cancer Res; 2005 Aug 15;65(16):7127-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of malignant and nonmalignant lesions of esophagus and stomach: differential activity of functional modules related to inflammation and lipid metabolism.
  • Adenocarcinomas of stomach and esophagus are frequently associated with preceding inflammatory alterations of the normal mucosa.
  • Whereas intestinal metaplasia of the gastric mucosa is associated with higher risk of malignization, Barrett's disease is a risk factor for adenocarcinoma of the esophagus.
  • Using cDNA microarrays, we determined the expression profile of normal gastric and esophageal mucosa as well as intestinal metaplasia and adenocarcinomas from both organs.
  • Data were explored to define functional alterations related to the transformation from squamous to columnar epithelium and the malignant transformation from intestinal metaplasia to adenocarcinomas.
  • Based on their expression profile, adenocarcinomas of the esophagus showed stronger correlation with intestinal metaplasia of the stomach than with Barrett's mucosa.
  • Whereas the lipid metabolism module is active in samples representing intestinal metaplasia and inactive in adenocarcinomas, the cytokine module is inactive in samples representing normal esophagus and esophagitis.
  • Exploitation of the data presented herein will help in the precise molecular characterization of adenocarcinoma from the distal esophagus, avoiding the topographical and descriptive classification that is currently adopted, and help with the proper management of patients with Barrett's disease.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Esophageal Neoplasms / genetics. Esophageal Neoplasms / metabolism. Lipid Metabolism. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103062.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


69. Ryan AM, Rowley SP, Fitzgerald AP, Ravi N, Reynolds JV: Adenocarcinoma of the oesophagus and gastric cardia: male preponderance in association with obesity. Eur J Cancer; 2006 May;42(8):1151-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the oesophagus and gastric cardia: male preponderance in association with obesity.
  • Recent evidence links obesity with the rising incidence of oesophageal adenocarcinoma.
  • In Ireland between 1995 and 2004 the incidence of oesophageal adenocarcinoma increased by 38%, and this coincided with a 67% increase in the prevalence of obesity.
  • In this study, a prospective case-control study was undertaken in 760 patients presenting to a tertiary centre between 1994 and 2004 diagnosed with cancer of the oesophagus, gastric cardia or stomach.
  • Multivariate logistic regression models were used to calculate the odds ratio (OR) of developing either cancer type according to quartiles of body mass index (BMI).
  • Based on pre-illness BMI, 82% of patients who developed adenocarcinoma of the oesophagus were either overweight or obese compared with 59% of the healthy control population (P<0.001).
  • A dose-dependent relationship existed between BMI and oesophageal adenocarcinoma in males.
  • Using common cut-off points for BMI, the OR of adenocarcinoma of the lower oesophagus was 11.3 times higher (95% CI: 3.5-36.4) for individuals with a BMI >30 kg/m2 versus individuals with a BMI <22 kg/m2 (P<0.001 for trend).
  • For adenocarcinoma of the gastric cardia, males in the top quartile of BMI had an OR of 3.5 (95% CI: 1.3-9.4) compared with the lowest quartile (P=0.03 for trend).
  • The odds ratio for adenocarcinoma of the oesophagus, the oesophago-gastric junction and gastric cardia rose significantly with increasing BMI.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Squamous Cell / etiology. Cardia. Esophageal Neoplasms / etiology. Obesity / complications. Stomach Neoplasms / etiology


70. Stathopoulos GP, Boulikas T, Vougiouka M, Deliconstantinos G, Rigatos S, Darli E, Viliotou V, Stathopoulos JG: Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol Rep; 2005 Apr;13(4):589-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacokinetics. Carcinoma, Squamous Cell / drug therapy. Cisplatin / adverse effects. Cisplatin / pharmacokinetics. Kidney Neoplasms / drug therapy. Liposomes / chemistry. Pancreatic Neoplasms / drug therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756428.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Lipids; 0 / Liposomes; 0 / Phosphatidylcholines; 0 / Phosphatidylethanolamines; 0 / Phosphatidylglycerols; 0 / lipoplatin; 0 / polyethylene glycol-distearoylphosphatidylethanolamine; 30IQX730WE / Polyethylene Glycols; 97C5T2UQ7J / Cholesterol; Q20Q21Q62J / Cisplatin; VA9U6BR3SB / 1,2-dipalmitoylphosphatidylglycerol
  •  go-up   go-down


71. Drescher D, Moehler M, Gockel I, Frerichs K, Müller A, Dünschede F, Borschitz T, Biesterfeld S, Holtmann M, Wehler T, Teufel A, Herzer K, Fischer T, Berger MR, Junginger T, Galle PR, Schimanski CC: Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy? World J Gastroenterol; 2007 Jul 14;13(26):3605-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy?
  • AIM: To define the (co-)expression pattern of target receptor-tyrosine-kinases (RTK) in human gastric adenocarcinoma.
  • METHODS: The (co-)expression pattern of VEGFR1-3, PDGFR alpha/beta and EGFR1 was analyzed by RT-PCR in 51 human gastric adenocarcinomas.
  • CONCLUSION: Our results reveal a high rate of receptor-tyrosine-kinases coexpression in gastric adenocarcinoma and might therefore encourage an application of multiple-target RTK-inhibitors within a combination therapy.
  • [MeSH-major] Adenocarcinoma / enzymology. Antineoplastic Agents / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Receptor Protein-Tyrosine Kinases / analysis. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Stomach Neoplasms / enzymology
  • [MeSH-minor] Drug Design. Drug Therapy, Combination. Gastric Mucosa / enzymology. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):165-73 [15197767.001]
  • [Cites] Mod Pathol. 2004 May;17(5):579-87 [15073595.001]
  • [Cites] Jpn J Cancer Res. 1989 Sep;80(9):813-7 [2557315.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3453-9 [1317752.001]
  • [Cites] Cancer. 1995 Mar 15;75(6 Suppl):1418-25 [7889468.001]
  • [Cites] CA Cancer J Clin. 1996 Jan-Feb;46(1):5-27 [8548526.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1679-84 [9816116.001]
  • [Cites] Thromb Haemost. 2004 Dec;92(6):1438-45 [15583754.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):485-94 [15475932.001]
  • [Cites] Dig Dis. 2004;22(4):302-5 [15812151.001]
  • [Cites] Dig Dis. 2004;22(4):345-50 [15812158.001]
  • [Cites] Dev Cell. 2005 Aug;9(2):197-207 [16054027.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2005 Oct;286(2):875-84 [16114069.001]
  • [Cites] Int J Clin Oncol. 2005 Oct;10(5):318-27 [16247658.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2323-33 [16240452.001]
  • [Cites] Lab Invest. 2006 Jan;86(1):94-100 [16258521.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):192-8 [16482617.001]
  • [Cites] Expert Opin Investig Drugs. 2006 May;15(5):553-61 [16634693.001]
  • [Cites] Clin Lung Cancer. 2006 Mar;7(5):304-8 [16640800.001]
  • [Cites] Biochemistry. 2006 May 23;45(20):6241-51 [16700535.001]
  • [Cites] J Clin Invest. 2006 Jun;116(6):1561-70 [16741576.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Mar;25(1):83-8 [16761623.001]
  • [Cites] Histol Histopathol. 2006 Sep;21(9):987-93 [16763949.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Drugs Today (Barc). 2006 Jun;42(6):387-98 [16845442.001]
  • [Cites] Verh Dtsch Ges Pathol. 2004;88:174-83 [16892550.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2624-31 [16638931.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):562-6 [11807778.001]
  • [Cites] Oncogene. 2003 Apr 17;22(15):2334-42 [12700668.001]
  • [Cites] Chin Med Sci J. 1999 Jun;14(2):107-11 [12901620.001]
  • [Cites] J Clin Invest. 2003 Oct;112(8):1134-6 [14561696.001]
  • [Cites] Eur J Surg Oncol. 2003 Dec;29(10):890-4 [14624783.001]
  • [Cites] World J Gastroenterol. 2004 Feb 1;10(3):352-5 [14760756.001]
  • [Cites] Rev Hosp Clin Fac Med Sao Paulo. 2004 Aug;59(4):172-80 [15361981.001]
  • (PMID = 17659711.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ PMC4146800
  •  go-up   go-down


72. Roh JH, Srivastava A, Lauwers GY, An J, Jang KT, Park CK, Sohn TS, Kim S, Kim KM: Micropapillary carcinoma of stomach: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol; 2010 Aug;34(8):1139-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micropapillary carcinoma of stomach: a clinicopathologic and immunohistochemical study of 11 cases.
  • Micropapillary carcinoma (MPC) of the stomach is a rare, newly recognized entity, and only 2 patients with this histology have been reported.
  • We investigated clinicopathologic features, expression of mucin (MUC2, MUC5AC, MUC6, CD10) and cytokeratin profiles (CK7 and CK20), epidermal growth factor receptors (EGFR and HER2), prognostic markers (p53 and Ki-67), and outcomes in 11 MPCs of the stomach.
  • In 9 conventional adenocarcinomas and 11 papillary adenocarcinomas with multiple endolymphatic tumor emboli, used as control, positive expression was observed for Ki-67 (100%), CK7 (90%), EGFR (80%), CK20 (70%), p53 (70%), MUC5AC (70%), MUC6 (60%), MUC2 (40%), CD10 (25%), and HER2 (15%).
  • Expression of MUC2, CK20, and the Ki-67 labeling index was significantly higher in control adenocarcinomas as compared with MPCs (P<0.05).
  • Although MPCs in other organs show a poor prognosis, this does not seem to be true for gastric MPCs.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Papillary / diagnosis. Biomarkers, Tumor / analysis. Immunohistochemistry. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Gastric Mucins / analysis. Humans. Kaplan-Meier Estimate. Keratins / analysis. Ki-67 Antigen / analysis. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Receptor, Epidermal Growth Factor / analysis. Receptor, ErbB-2 / analysis. Republic of Korea. Time Factors. Treatment Outcome. Tumor Suppressor Protein p53 / analysis


73. Giannakis M, Chen SL, Karam SM, Engstrand L, Gordon JI: Helicobacter pylori evolution during progression from chronic atrophic gastritis to gastric cancer and its impact on gastric stem cells. Proc Natl Acad Sci U S A; 2008 Mar 18;105(11):4358-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori evolution during progression from chronic atrophic gastritis to gastric cancer and its impact on gastric stem cells.
  • We have characterized the adaptations of Helicobacter pylori to a rarely captured event in the evolution of its impact on host biology-the transition from chronic atrophic gastritis (ChAG) to gastric adenocarcinoma-and defined the impact of these adaptations on an intriguing but poorly characterized interaction between this bacterium and gastric epithelial stem cells.
  • Bacterial isolates were obtained from a single human host colonized with a single dominant strain before and after his progression from ChAG to gastric adenocarcinoma during a 4-year interval.
  • Draft genome assemblies were generated from two isolates, one ChAG-associated, the other cancer-associated.
  • The cancer-associated strain was less fit in a gnotobiotic transgenic mouse model of human ChAG and better able to establish itself within a mouse gastric epithelial progenitor-derived cell line (mGEP) that supports bacterial attachment.
  • GeneChip-based comparisons of the transcriptomes of mGEPs and a control mouse gastric epithelial cell line revealed that, upon infection, the cancer-associated strain regulates expression of GEP-associated signaling and metabolic pathways, and tumor suppressor genes associated with development of gastric cancer in humans, in a manner distinct from the ChAG-associated isolate.
  • The effects on GEP metabolic pathways, some of which were confirmed in gnotobiotic mice, together with observed changes in the bacterial transcriptome are predicted to support aspects of an endosymbiosis between this microbe and gastric stem cells.
  • These results provide insights about how H. pylori may adapt to and influence stem cell biology and how its intracellular residency could contribute to gastric tumorigenesis.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • REBASE - The Restriction Enzyme Database. gene/protein/disease-specific - REBASE ref# 11391 .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • SILVA. SILVA LSU Database .
  • SILVA. SILVA SSU Database .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2397-405 [15059891.001]
  • [Cites] Int J Cancer. 2004 Mar10;109(1):138-43 [14735480.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):781-92 [15510159.001]
  • [Cites] Nucleic Acids Res. 1992 Oct 11;20(19):5137-42 [1408828.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241 [7715068.001]
  • [Cites] Mol Microbiol. 1996 Apr;20(2):361-73 [8733234.001]
  • [Cites] J Immunol. 1997 Jan 15;158(2):962-7 [8993017.001]
  • [Cites] Nature. 1997 Aug 7;388(6642):539-47 [9252185.001]
  • [Cites] Gastroenterology. 1998 Feb;114(2):256-61 [9453484.001]
  • [Cites] Nature. 1999 Jan 14;397(6715):176-80 [9923682.001]
  • [Cites] Mol Cell. 1999 Mar;3(3):263-74 [10198629.001]
  • [Cites] Nucleic Acids Res. 1999 Aug 15;27(16):3325-33 [10454640.001]
  • [Cites] Microbiol Mol Biol Rev. 1999 Sep;63(3):675-707 [10477312.001]
  • [Cites] Scand J Gastroenterol. 2004 Dec;39(12):1280-8 [15743007.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5186-91 [15795379.001]
  • [Cites] J Pathol. 2005 May;206(1):100-10 [15809971.001]
  • [Cites] Infect Immun. 2005 Aug;73(8):4732-42 [16040986.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10646-51 [16027366.001]
  • [Cites] J Biol Chem. 2006 Apr 21;281(16):11292-300 [16464855.001]
  • [Cites] J Biol Chem. 2006 May 26;281(21):14529-32 [16459331.001]
  • [Cites] Cell. 2006 Jun 16;125(6):1151-63 [16777604.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9999-10004 [16788065.001]
  • [Cites] Cell Mol Life Sci. 2006 Sep;63(18):2095-101 [16847581.001]
  • [Cites] Genomics. 2007 Apr;89(4):451-9 [17229543.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):1009-23 [17383424.001]
  • [Cites] World J Gastroenterol. 2007 May 28;13(20):2867-71 [17569126.001]
  • [Cites] Cell Prolif. 2008 Apr;41(2):310-20 [18336475.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Genomics. 2000 Nov 1;69(3):281-6 [11056045.001]
  • [Cites] Nature. 2001 Jan 11;409(6817):211-5 [11196647.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14819-24 [12409607.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3467-72 [12629225.001]
  • [Cites] J Pathol. 2003 May;200(1):39-46 [12692839.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):46008-13 [15326188.001]
  • (PMID = 18332421.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Databank-accession-numbers] GENBANK/ ABJO00000000/ ABJO01000000/ ABJP00000000/ ABJP01000000; GEO/ GSE10261/ GSE10262
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK058529; United States / NIDDK NIH HHS / DK / DK58529; United States / NIAID NIH HHS / AI / AI068362; United States / NIDDK NIH HHS / DK / P50 DK064540; United States / NIAID NIH HHS / AI / F32 AI068362; United States / NIDDK NIH HHS / DK / U01 DK063483; United States / NIGMS NIH HHS / GM / T32 GM007200; United States / NIDDK NIH HHS / DK / DK52574; United States / NIDDK NIH HHS / DK / DK63483; United States / NIGMS NIH HHS / GM / GM07200; United States / NIDDK NIH HHS / DK / P30 DK052574; United States / NIDDK NIH HHS / DK / DK64540
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2393758
  •  go-up   go-down


74. Martínez-Noguera A, D'Onofrio M: Ultrasonography of the pancreas. 1. Conventional imaging. Abdom Imaging; 2007 Mar-Apr;32(2):136-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article reviews the wide utility of US and the many examinations techniques, such as filling the stomach with water, changing the patient's position or suspending inspiration or expiration, allowing us to visualize all portions of the pancreas in a high percentage of patients.
  • [MeSH-minor] Adenocarcinoma / ultrasonography. Humans. Pancreatic Neoplasms / ultrasonography. Pancreatitis / ultrasonography

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16897275.001).
  • [ISSN] 0942-8925
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 66
  •  go-up   go-down


75. Ong SJ, Teo M, Lim KH, Choo SP, Toh HC: Rapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report. Oncologist; 2010;15(9):965-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Esophagogastric Junction. Stomach Neoplasms / drug therapy


76. Díaz de Liaño A, Yarnoz C, Aguilar R, Artieda C, Ortiz H: Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer. Gastric Cancer; 2008;11(2):96-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer.
  • BACKGROUND: In the surgical management of gastric cancer, D2 lymphadenectomy aims to reduce the incidence of locoregional relapse, and to increase patient survival.
  • METHODS: A prospective study was made of 126 consecutive patients operated upon for gastric cancer, with gastrectomy and D2 lymphadenectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy / methods. Lymph Node Excision. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastric Cancer. 2008;11(2):69-71 [18595012.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Br J Cancer. 2001 Jan 5;84(1):64-71 [11139315.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1489-94 [11100384.001]
  • [Cites] Br J Surg. 1988 Feb;75(2):110-2 [3349293.001]
  • [Cites] Surgery. 2002 Apr;131(4):401-7 [11935130.001]
  • [Cites] World J Surg. 1997 Jul-Aug;21(6):622-7; discussion 627-8 [9230660.001]
  • [Cites] Ann Surg. 1997 Nov;226(5):613-20 [9389395.001]
  • [Cites] Br J Surg. 1993 Aug;80(8):1015-8 [8402053.001]
  • [Cites] Br J Surg. 2006 Mar;93(3):325-31 [16498603.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):159-65 [12170020.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2089-97 [8374867.001]
  • [Cites] Br J Surg. 1997 Nov;84(11):1567-71 [9393281.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):894-900 [12417512.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):828-30 [12417502.001]
  • [Cites] Surgery. 1998 May;123(5):573-8 [9591011.001]
  • [Cites] Ann Surg Oncol. 2001 Sep;8(8):620-1 [11569774.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):362-71 [10973386.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):808-16 [15492562.001]
  • [Cites] Br J Surg. 2000 Mar;87(3):353-7 [10718807.001]
  • [Cites] Am Surg. 1995 Apr;61(4):371-6 [7893109.001]
  • [Cites] Gastric Cancer. 2004;7(4):196-201; discussion 201-203 [15616767.001]
  • [Cites] Ann Surg Oncol. 2002 May;9(4):394-400 [11986192.001]
  • [Cites] Br J Surg. 2000 Feb;87(2):236-42 [10671934.001]
  • [Cites] Ann Surg. 1996 Jul;224(1):37-42 [8678615.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1160-5 [12209247.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):247-55 [15650634.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2117-27 [14645640.001]
  • [Cites] Br J Surg. 2002 Jan;89(1):123 [11851682.001]
  • [Cites] Gastric Cancer. 1999 Nov;2(3):151-157 [11957089.001]
  • [Cites] Gastric Cancer. 2002;5(1):29-34 [12021857.001]
  • [Cites] J Am Coll Surg. 2005 Oct;201(4):503-10 [16183487.001]
  • [Cites] Int Surg. 1997 Jul-Sep;82(3):257-61 [9372370.001]
  • [Cites] Gastric Cancer. 2004;7(4):254-9 [15616774.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):27-39 [15621988.001]
  • [Cites] Br J Surg. 1992 Oct;79(10):1091-4 [1422730.001]
  • [Cites] Br J Surg. 1996 Jun;83(6):726-33 [8696727.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):904-6 [10919059.001]
  • (PMID = 18595016.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


77. Huh JW, Park YA, Lee KY, Sohn SK: Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication. Yonsei Med J; 2009 Oct 31;50(5):697-703
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication.
  • PURPOSE: Adenosine triphosphate-based chemotherapy response assay (ATP-CRA) is a well-documented and validated technology that can individualize chemotherapy for patients with lung, stomach, or breast cancer.
  • This study explored the feasibility of ATP-CRA as a chemosensitivity test in patients with colorectal cancer.
  • MATERIALS AND METHODS: A total of 118 patients who underwent surgical resection for colorectal adenocarcinoma were analyzed for chemosensitivity to 6 anticancer drugs using ATP-CRA.
  • CONCLUSION: Our study suggests that ATP-CRA could be used to identify patients with colorectal cancer who might benefit from treatment with a specific chemotherapeutic agent.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenosine Triphosphate / metabolism. Antineoplastic Agents / pharmacology. Colorectal Neoplasms / drug therapy. Drug Screening Assays, Antitumor / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):405-8 [10684718.001]
  • [Cites] J Korean Med Sci. 2008 Oct;23(5):916-9 [18955806.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):872-9 [11978511.001]
  • [Cites] Anticancer Drugs. 2003 Jun;14(5):369-75 [12782944.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] Pharm Res. 2004 Mar;21(3):406-12 [15070089.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3618-30 [15289487.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3631-8 [15289488.001]
  • [Cites] Cancer Res. 1982 Jun;42(6):2159-64 [7074595.001]
  • [Cites] Cancer Treat Rev. 1984 Mar;11 Suppl A:113-24 [6428738.001]
  • [Cites] Recent Results Cancer Res. 1984;94:1-7 [6494573.001]
  • [Cites] Hematol Oncol. 1985 Jan-Mar;3(1):1-10 [2580768.001]
  • [Cites] Cancer Treat Rep. 1986 Nov;70(11):1283-95 [2429763.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jul;84(14):5029-33 [3474637.001]
  • [Cites] Gynecol Oncol. 1988 Sep;31(1):191-204 [3410347.001]
  • [Cites] J Surg Oncol. 1989 Jan;40(1):4-7 [2909804.001]
  • [Cites] Eur J Cancer. 1991;27(10):1258-63 [1835595.001]
  • [Cites] J Biolumin Chemilumin. 1995 Jan-Feb;10(1):29-34 [7762413.001]
  • [Cites] Anticancer Drugs. 1996 Aug;7(6):630-5 [8913430.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):960-6 [9291821.001]
  • [Cites] Ann Intern Med. 1998 Jul 1;129(1):27-35 [9652996.001]
  • [Cites] Clin Cancer Res. 1995 Mar;1(3):305-11 [9815986.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1487-93 [10188895.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1625-31 [10334552.001]
  • [Cites] Anticancer Drugs. 1999 Jun;10(5):437-44 [10477162.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3453-9 [16101163.001]
  • [Cites] Cell Cycle. 2006 Apr;5(8):818-23 [16628000.001]
  • [Cites] Int J Clin Oncol. 2006 Dec;11(6):449-53 [17180513.001]
  • [Cites] Cancer. 2007 May 1;109(9):1829-35 [17366594.001]
  • [Cites] Gynecol Oncol. 2000 May;77(2):258-63 [10785475.001]
  • (PMID = 19881975.001).
  • [ISSN] 1976-2437
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 8L70Q75FXE / Adenosine Triphosphate
  • [Other-IDs] NLM/ PMC2768246
  • [Keywords] NOTNLM ; Adenosine triphosphate / chemotherapy response assay / colorectal cancer
  •  go-up   go-down


78. Ponti G, Luppi G, Losi L, Giannetti A, Seidenari S: Leser-Trélat syndrome in patients affected by six multiple metachronous primitive cancers. J Hematol Oncol; 2010;3:2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Usually, the sign of Leser-Trélat is associated with adenocarcinoma, most frequently of the colon, breast, or stomach, but also of the lung, kidney, liver, and pancreas.
  • Herein, we present a case that we believe is the first report of the sign of Leser-Trélat in association with occult gastric adenocarcinoma and the anamnestic oncologic history of five other multiple primitive cancers.
  • [MeSH-major] Adenocarcinoma / diagnosis. Intestinal Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis. Neoplastic Syndromes, Hereditary / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Humans. Keratosis, Seborrheic / complications. Keratosis, Seborrheic / diagnosis. Male

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):947-50 [1535080.001]
  • [Cites] J Med Genet. 2005 Nov;42(11):801-10 [15958502.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):980-7 [16321766.001]
  • [Cites] Lancet Oncol. 2008 May;9(5):462-72 [18452857.001]
  • [Cites] Clin Exp Dermatol. 1988 May;13(3):177-9 [2977576.001]
  • [Cites] Acta Derm Venereol. 1991;71(2):166-9 [1675530.001]
  • [Cites] J Am Acad Dermatol. 2000 Aug;43(2 Pt 2):386-90 [10901731.001]
  • [Cites] N Engl J Med. 1987 Dec 17;317(25):1582-7 [2825016.001]
  • [Cites] Aust Fam Physician. 2009 Jul;38(7):498-505 [19575068.001]
  • (PMID = 20064244.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2820021
  •  go-up   go-down


79. Lindén S, Semino-Mora C, Liu H, Rick J, Dubois A: Role of mucin Lewis status in resistance to Helicobacter pylori infection in pediatric patients. Helicobacter; 2010 Aug;15(4):251-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Helicobacter pylori causes gastritis, peptic ulcer and is a risk factor for adenocarcinoma and lymphoma of the stomach.
  • Gastric mucins, carrying highly diverse carbohydrate structures, present functional binding sites for H. pylori and may play a role in pathogenesis.
  • However, little information is available regarding gastric mucin in children with and without stomach diseases.
  • MATERIALS AND METHODS: Expression of mucins and glycosylation was studied by immunohistochemistry on gastric biopsies from 51 children with and without H. pylori infection and/or peptic ulcer disease.
  • The Le(b) and Le(a) blood group antigens were present in the surface epithelium of 80% and 29% of children, respectively. H. pylori load was higher in Le(b) negative children than in Le(b) positive individuals (mean +/- SEM 17.8 +/- 3.5 vs 10.8 +/- 1.5; p < 0.05), but there was no correlation between Le(a) or Le(b) status and gastritis, nodularity, and gastric or duodenal ulcer (DU).
  • Furthermore, the lower H. pylori density in Le(b) positive children indicates that H. pylori is suppressed in the presence of gastric mucins decorated with Le(b), the binding site of the H. pylori BabA adhesin.

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Gastroenterol Nutr. 2000 Jul;31(1):63-7 [10896073.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12778-83 [10535999.001]
  • [Cites] Scand J Gastroenterol. 2000 Oct;35(10):1033-40 [11099055.001]
  • [Cites] Gerontology. 2000 May-Jun;46(3):153-7 [10754373.001]
  • [Cites] J Histochem Cytochem. 2000 Dec;48(12):1657-66 [11101634.001]
  • [Cites] J Clin Gastroenterol. 2001 Mar;32(3):218-21 [11246347.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1903-9 [11280745.001]
  • [Cites] Biochem J. 2002 May 15;364(Pt 1):191-200 [11988092.001]
  • [Cites] Sao Paulo Med J. 2002 Mar 7;120(2):55-8 [11994774.001]
  • [Cites] Science. 2002 Jul 26;297(5581):573-8 [12142529.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2002;35 Suppl 2:S128-33 [12192181.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1923-30 [12454849.001]
  • [Cites] Pediatr Pathol Mol Med. 2003 Mar-Apr;22(2):117-29 [12556292.001]
  • [Cites] J Infect Dis. 2003 Apr 15;187(8):1165-77 [12695995.001]
  • [Cites] Helicobacter. 2003 Jun;8(3):216-26 [12752734.001]
  • [Cites] Gut. 2003 Jul;52(7):927-32 [12801945.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5604-8 [14662948.001]
  • [Cites] Biochem J. 2004 May 1;379(Pt 3):765-75 [14736333.001]
  • [Cites] J Clin Pathol. 2004 Aug;57(8):861-6 [15280409.001]
  • [Cites] Science. 2004 Aug 13;305(5686):1003-6 [15310903.001]
  • [Cites] Lab Invest. 1985 Aug;53(2):219-27 [2410664.001]
  • [Cites] Am J Clin Pathol. 1992 Jul;98(1):67-75 [1615929.001]
  • [Cites] APMIS Suppl. 1992;27:28-38 [1520528.001]
  • [Cites] Science. 1993 Dec 17;262(5141):1892-5 [8018146.001]
  • [Cites] Hum Pathol. 1994 Mar;25(3):221-6 [7512070.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):723-34 [7657100.001]
  • [Cites] Vox Sang. 1995;69(3):166-82 [8578728.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):455-64 [9247464.001]
  • [Cites] Helicobacter. 1996 Dec;1(4):207-18 [9398871.001]
  • [Cites] Science. 1998 Jan 16;279(5349):373-7 [9430586.001]
  • [Cites] FEMS Immunol Med Microbiol. 1998 Apr;20(4):257-66 [9626930.001]
  • [Cites] Biochem J. 1998 Sep 15;334 ( Pt 3):685-93 [9729478.001]
  • [Cites] Gastroenterology. 1998 Nov;115(5):1113-22 [9797366.001]
  • [Cites] Virchows Arch. 1998 Nov;433(5):419-26 [9849856.001]
  • [Cites] Gut. 1998 Oct;43(4):519-24 [9824580.001]
  • [Cites] JAMA. 1999 Jan 6;281(1):10-1 [9892430.001]
  • [Cites] J Biol Chem. 1999 May 28;274(22):15828-36 [10336486.001]
  • [Cites] J Clin Pathol. 1999 Feb;52(2):137-40 [10396242.001]
  • [Cites] Biochem J. 2004 Dec 1;384(Pt 2):263-70 [15260802.001]
  • [Cites] Joint Bone Spine. 2005 Mar;72(2):135-41 [15797493.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Feb;21(2):425-31 [16509869.001]
  • [Cites] Gut. 2006 Jun;55(6):775-81 [16322107.001]
  • [Cites] Annu Rev Pathol. 2006;1:63-96 [18039108.001]
  • [Cites] PLoS Pathog. 2008 Jan;4(1):e2 [18179282.001]
  • [Cites] Helicobacter. 2008 Apr;13(2):81-93 [18321298.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2010 Feb;50(2):167-72 [20038850.001]
  • [Cites] Ann Diagn Pathol. 2000 Oct;4(5):279-85 [11073332.001]
  • (PMID = 20633185.001).
  • [ISSN] 1523-5378
  • [Journal-full-title] Helicobacter
  • [ISO-abbreviation] Helicobacter
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA082312; United States / NCI NIH HHS / CA / CA82312
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gastric Mucins; 0 / Lewis Blood-Group System
  • [Other-IDs] NLM/ NIHMS328045; NLM/ PMC3209514
  •  go-up   go-down


80. Fock KM, Talley N, Moayyedi P, Hunt R, Azuma T, Sugano K, Xiao SD, Lam SK, Goh KL, Chiba T, Uemura N, Kim JG, Kim N, Ang TL, Mahachai V, Mitchell H, Rani AA, Liou JM, Vilaichone RK, Sollano J, Asia-Pacific Gastric Cancer Consensus Conference: Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol; 2008 Mar;23(3):351-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asia-Pacific consensus guidelines on gastric cancer prevention.
  • BACKGROUND AND AIM: Gastric cancer is a major health burden in the Asia-Pacific region but consensus on prevention strategies has been lacking.
  • We aimed to critically evaluate strategies for preventing gastric cancer.
  • RESULTS: Helicobacter pylori infection is a necessary but not sufficient causal factor for non-cardia gastric adenocarcinoma.
  • A high intake of salt is strongly associated with gastric cancer.
  • Fresh fruits and vegetables are protective but the use of vitamins and other dietary supplements does not prevent gastric cancer.
  • Host-bacterial interaction in H. pylori infection results in different patterns of gastritis and differences in gastric acid secretion which determine disease outcome.
  • A positive family history of gastric cancer is an important risk factor.
  • Low serum pepsinogens reflect gastric atrophy and may be useful as a marker to identify populations at high risk for gastric cancer. H. pylori screening and treatment is a recommended gastric cancer risk reduction strategy in high-risk populations. H. pylori screening and treatment is most effective before atrophic gastritis has developed.
  • It does not exclude the existing practice of gastric cancer surveillance in high-risk populations.
  • In populations at low risk for gastric cancer, H. pylori screening is not recommended.
  • CONCLUSION: A strategy of H. pylori screening and eradication in high-risk populations will probably reduce gastric cancer incidence, and based on current evidence is recommended by consensus.
  • [MeSH-major] Adenocarcinoma / prevention & control. Anticarcinogenic Agents / therapeutic use. Biomarkers, Tumor / analysis. Helicobacter Infections / drug therapy. Helicobacter pylori. Mass Screening. Stomach Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318820.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anticarcinogenic Agents; 0 / Biomarkers, Tumor; 0 / Pepsinogens; 0 / Sodium Chloride, Dietary; 0 / Vitamins; PQ6CK8PD0R / Ascorbic Acid
  • [Number-of-references] 140
  •  go-up   go-down


81. Al-Moundhri MS, Al-Bahrani B, Burney IA, Nirmala V, Al-Madhani A, Al-Mawaly K, Al-Nabhani M, Thomas V, Ganguly SS, Grant CS: The prognostic determinants of gastric cancer treatment outcome in Omani Arab patients. Oncology; 2006;70(2):90-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic determinants of gastric cancer treatment outcome in Omani Arab patients.
  • BACKGROUND: Gastric cancer is the most common cancer in Oman and a leading cause of cancer death.
  • There were no previous reports on gastric cancer from Oman and very few studies on Asian Arabs.
  • AIM: To evaluate the impact of clinicopathological and treatment variables on the survival prospects of Omani Arab patients diagnosed with gastric cancer.
  • METHODS: The medical records of 339 Omani Arab patients diagnosed with invasive gastric adenocarcinoma during the period 1993-2004 were retrospectively reviewed.
  • RESULTS: Most patients had distal ulcerating-type gastric cancer and presented at advanced stages.
  • More efforts need to be made for the early detection of gastric cancer in developing countries such as Oman, while continuing to employ the standard surgical and medical treatments.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Arabs / statistics & numerical data. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16601367.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


82. Alves MK, Lima VP, André AR, Ferreira MV, Barros MA, Rabenhorst SH: p27KIP1 expression in gastric cancer: differential pathways in the histological subtypes associated with Helicobacter pylori infection. Scand J Gastroenterol; 2010 Apr;45(4):409-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p27KIP1 expression in gastric cancer: differential pathways in the histological subtypes associated with Helicobacter pylori infection.
  • Therefore, in a series of gastric adenocarcinomas we studied the association of p27(KIP1) expression with H. pylori genotype (vacA, cagA, cagE and virB11) and the involvement of C-MYC in this process.
  • MATERIAL AND METHODS: Expression of p27(KIP1) and C-MYC was determined by immunohistochemistry in 84 gastric adenocarcinoma samples and H. pylori infection and genotype were determined by polymerase chain reaction.
  • In the diffuse gastric cancer subtype, p27-negative-C-MYC-positive was the most frequent combination (cluster II), and was associated with the more pathogenic H. pylori strains.
  • Although an association with p27(KIP1) and H. pylori strain was found in the intestinal gastric cancer subtype, negativity for p27(KIP1) and C-MYC markers was the most frequent cluster, followed by cluster II, and both were present, independent of the H. pylori genotype.
  • These data add insight to the differential influence and relevance of H. pylori genotype in gastric cancer development.
  • [MeSH-major] Adenocarcinoma / genetics. Helicobacter Infections / genetics. Helicobacter pylori / genetics. Helicobacter pylori / pathogenicity. Intracellular Signaling Peptides and Proteins / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20059402.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / CDKN1B protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / PicB protein, Helicobacter pylori; 0 / VacA protein, Helicobacter pylori; 0 / cagA protein, Helicobacter pylori; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


83. Wakatsuki K, Yoshioka S, Kataoka M, Tonooka T, Kawamoto J, Oeda Y: [A case of advanced gastric cancer responding completely treated with S-1 therapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2303-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer responding completely treated with S-1 therapy].
  • Gastroscopy revealed a gastric carcinoma.
  • Pathology revealed no cancer cells in the gastric wall and dissected lymph nodes.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037403.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  • [Number-of-references] 14
  •  go-up   go-down


84. Zhou Y, Li G, Wu J, Zhang Z, Wu Z, Fan P, Hao T, Zhang X, Li M, Zhang F, Li Q, Lu B, Qiao L: Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. Tumour Biol; 2010 Dec;31(6):549-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer.
  • In this study, we examined the expressions of E-cadherin, VEGF, MMP-1, MMP-2, and microvessel density (MVD), as well as microlymphatic vessel density (MLVD) in 200 cases of gastric cancer tissues, and determined the relationship between these parameters and the clinicopathological features and patient survival.
  • Compared to normal gastric mucosa, expression of E-cadherin was reduced in 78% of gastric cancer tissues and 44.6% of adjacent non-cancerous gastric tissues.
  • VEGF was positive in 81.5% of gastric cancer tissues, 35.7% of adjacent non-cancerous gastric tissues, and 10% of normal gastric mucosa.
  • MMP-1 was positive in 80.5% of gastric cancer tissues, 69.6% of adjacent non-cancerous gastric tissues, and 20% of normal gastric mucosa.
  • Therefore, abnormal expressions of E-cadherin, VEGF, MMP-1, and MMP-2 are widely present in gastric cancer tissues.
  • Abnormal expressions of E-cadherin, VEGF, and MMP-2 may represent the early molecular changes in the development of gastric cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Cadherins / metabolism. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 2 / metabolism. Stomach Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Female. Gastric Mucosa / blood supply. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Kaplan-Meier Estimate. Lymphatic Vessels / pathology. Male. Microvessels / pathology. Middle Aged. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1996 Apr 15;77(8 Suppl):1605-13 [8608551.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10185-90 [18632559.001]
  • [Cites] Cancer Invest. 2008 May;26(4):375-84 [18443958.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):333-9 [9708792.001]
  • [Cites] Cancer Lett. 2008 Sep 18;268(2):260-71 [18477501.001]
  • [Cites] Br J Cancer. 1999 Feb;79(5-6):780-6 [10070869.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3579-83 [17094486.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):1035-40 [16538217.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] Curr Opin Cell Biol. 2001 Oct;13(5):534-40 [11544020.001]
  • [Cites] Cancer. 2007 Apr 15;109(8):1478-86 [17340592.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):858-63 [8608475.001]
  • [Cites] J Med Invest. 2001 Feb;48(1-2):31-43 [11286015.001]
  • [Cites] Ann Med. 1999 Feb;31(1):34-45 [10219712.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):9-19 [7541613.001]
  • [Cites] Hum Pathol. 1994 Sep;25(9):849-56 [8088758.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):634-40 [14760086.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):765-70 [17429393.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14 (15):4743-50 [18676743.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):847-54 [18507028.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):269-75 [17224647.001]
  • [Cites] Folia Neuropathol. 2009;47(4):338-46 [20054786.001]
  • (PMID = 20563765.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


85. Liu WT, Jiao HL, Yang YL, Wang D, Zhang WM: [Correlation of E-cadherin hypermethylation to tumorigenesis and development of gastric cancer]. Ai Zheng; 2007 Nov;26(11):1199-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of E-cadherin hypermethylation to tumorigenesis and development of gastric cancer].
  • This study was to explore the correlation of E-cadherin hypermethylation to tumorigenesis and development of gastric cancer.
  • METHODS: Methylation-specific polymerase chain reaction (MSP) was used to detect the methylation of E-cad gene in 41 specimens of gastric cancer, 40 specimens of premalignant gastric lesions and 38 specimens of normal gastric tissues.
  • RESULTS: The positive rate of E-cad gene methylation was significantly higher in gastric cancer than in premalignant lesions and normal tissues (19.5% vs. 2.5% and 0.0%, P<0.05).
  • The positive rate of E-cad protein was significantly lower in gastric cancer tissues than in premalignant lesions and normal tissues (70.7% vs. 97.5% and 100.0%, P<0.05).
  • The positive rate of E-cad gene methylation was significantly higher in poorly differentiated cancer tissues than in well differentiated cancer tissues (43.8% vs. 4.0%, P<0.05), significantly higher in gastric cancer tissues with lymph node metastasis than in those without lymph node metastasis (33.3% vs. 5.0%, P<0.05), and significantly higher in gastric cancer tissues with serosa invasion than in those without serosa invasion (35.0% vs. 4.8%, P<0.05).
  • The positive rate of E-cad protein was significantly lower in gastric cancer tissues with E-cad gene methylation than in those without E-cad gene methylation (0.0% vs. 87.9%, P<0.05).
  • CONCLUSION: CpG island hypermethylation of E-cad gene exists in gastric cancer, which down-regulates E-cad expression and might be involved in tumorigenesis and development of gastric cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Cadherins / metabolism. DNA Methylation. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / genetics. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adult. Aged. Base Sequence. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. CpG Islands. Down-Regulation. Female. Gastric Mucosa / metabolism. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991318.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


86. Chandrasoma P, Makarewicz K, Wickramasinghe K, Ma Y, Demeester T: A proposal for a new validated histological definition of the gastroesophageal junction. Hum Pathol; 2006 Jan;37(1):40-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Present definitions of the gastroesophageal junction (GEJ) are the point of flaring of the tubular esophagus and the proximal limit of the gastric rugal folds.
  • Ten esophagogastrectomy specimens, in which there was a well-defined point of flaring of the tubular esophagus that coincided with the proximal limit of gastric rugal folds, were examined by complete histological mapping to evaluate the distribution of esophageal submucosal glands and surface epithelial types.
  • This results in an error, where up to 2.05 cm of distal reflux-damaged dilated esophagus can be mistaken as proximal stomach when presently accepted definitions for the GEJ are used.
  • The true GEJ is the proximal limit of gastric oxyntic mucosa defined by histology.
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Epithelial Cells / pathology. Esophageal Neoplasms / pathology. Esophagectomy. Female. Gastric Mucosa / pathology. Humans. Male. Middle Aged. Mucous Membrane / pathology

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360414.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Ohnishi N, Yuasa H, Tanaka S, Sawa H, Miura M, Matsui A, Higashi H, Musashi M, Iwabuchi K, Suzuki M, Yamada G, Azuma T, Hatakeyama M: Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci U S A; 2008 Jan 22;105(3):1003-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection with cagA-positive Helicobacter pylori is associated with gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma of B cell origin.
  • The cagA-encoded CagA protein is delivered into gastric epithelial cells via the bacterial type IV secretion system and, upon tyrosine phosphorylation by Src family kinases, specifically binds to and aberrantly activates SHP-2 tyrosine phosphatase, a bona fide oncoprotein in human malignancies.
  • Here, we generated transgenic mice expressing wild-type or phosphorylation-resistant CagA throughout the body or predominantly in the stomach.
  • Wild-type CagA transgenic mice showed gastric epithelial hyperplasia and some of the mice developed gastric polyps and adenocarcinomas of the stomach and small intestine.

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14559-64 [10588744.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1229-42 [15887107.001]
  • [Cites] Science. 2002 Jan 25;295(5555):683-6 [11743164.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):6775-8 [11788577.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):28-37 [11902583.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14428-33 [12391297.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):745-55 [12419219.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):249-55 [12719469.001]
  • [Cites] Bioessays. 2003 Jun;25(6):542-53 [12766944.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):148-50 [12717436.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17205-16 [14963045.001]
  • [Cites] Nat Med. 2004 Aug;10(8):849-57 [15273746.001]
  • [Cites] Blood. 2005 Jul 1;106(1):311-7 [15761018.001]
  • [Cites] Eur J Med Genet. 2005 Apr-Jun;48(2):81-96 [16053901.001]
  • [Cites] J Exp Med. 2005 Nov 7;202(9):1235-47 [16275761.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):261-76 [16354697.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1181-90 [16618412.001]
  • [Cites] Annu Rev Biochem. 2006;75:137-63 [16756488.001]
  • [Cites] Nature. 2007 May 17;447(7142):330-3 [17507984.001]
  • [Cites] Oncogene. 2007 May 24;26(24):3462-72 [17160020.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4617-26 [17237808.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1909-25 [15314019.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):688-94 [15343275.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] J Biol Chem. 1993 Dec 15;268(35):26559-70 [8253786.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1267-71 [8145781.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):160-4 [7816809.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 6;87(23):1777-80 [7473834.001]
  • [Cites] Am J Clin Pathol. 1996 Nov;106(5):670-5 [8929480.001]
  • [Cites] Trends Genet. 1996 May;12(5):171-5 [8984731.001]
  • [Cites] J Pharmacol Exp Ther. 1997 Jan;280(1):225-31 [8996200.001]
  • [Cites] Gut. 1997 Mar;40(3):297-301 [9135515.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5499-507 [9271425.001]
  • [Cites] Am J Gastroenterol. 1998 Mar;93(3):375-9 [9517643.001]
  • [Cites] Gastroenterology. 1998 Sep;115(3):642-8 [9721161.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4255-9 [9766647.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8816-20 [15604238.001]
  • [Cites] Blood. 2001 Feb 15;97(4):911-4 [11159516.001]
  • (PMID = 18192401.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / cagA protein, Helicobacter pylori; 21820-51-9 / Phosphotyrosine
  • [Other-IDs] NLM/ PMC2242726
  •  go-up   go-down


88. Liu H, Ubukata H, Tabuchi T, Takemura A, Motohashi G, Nishimura M, Satani T, Hong J, Katano M, Nakada I, Saniabadi AR, Tabuchi T: It is possible that tumour-infiltrating granulocytes promote tumour progression. Oncol Rep; 2009 Jul;22(1):29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using immunnostaining, we retrospectively investigated TIGs and FasL in 130 tissue specimens from gastric carcinoma.
  • Our results suggest that TIGs are conveniently measured by the immunostaining method, and possibly serve as an independent factor of prognosis in patients with gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / immunology. Granulocytes / immunology. Stomach Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19513501.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / FASLG protein, human; 0 / Fas Ligand Protein
  •  go-up   go-down


89. Yamashita H, Kitayama J, Shida D, Ishikawa M, Hama K, Aoki J, Arai H, Nagawa H: Differential expression of lysophosphatidic acid receptor-2 in intestinal and diffuse type gastric cancer. J Surg Oncol; 2006 Jan 1;93(1):30-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of lysophosphatidic acid receptor-2 in intestinal and diffuse type gastric cancer.
  • Recently, it was reported that malignant transformation resulted in aberrant expression of LPA2 in a various type of cancer, suggesting the positive role of LPA2 in tumor development.
  • METHODS: We investigated the expression of the LPA2 receptor immunohistochemically in 204 gastric cancers and analyzed the relationship between the expression of LPA2 and clinicopathological features.
  • RESULTS: LPA2 was preferentially expressed (67%) in intestinal-type cancer that was significantly higher than that in diffuse-type cancer (32%, P < 0.0001).
  • The expression of LPA2 showed correlation with a higher rate of lymphatic and venous invasion, lymphatic metastasis, and resultingly tumor stage in diffuse-type cancer, but not in intestinal-type cancer.
  • CONCLUSIONS: Our results highlight the possibility that LPA2 expression is an important process in the carcinogenesis of gastric cancer, especially in intestinal-type cancer.
  • Since LPA can transactivate HGF receptor (c-Met) as well as EGF-receptor, LPA may promote the progression of gastric cancer in diffuse-type with high expression of c-Met.
  • The development of LPA2-specific antagonists might have future therapeutic relevance in the treatment as well as prevention of gastric cancer.
  • [MeSH-major] Lymph Nodes / pathology. Receptors, Lysophosphatidic Acid / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Female. Gastrectomy. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness


90. Deng H, Huang X, Fan J, Wang L, Xia Q, Yang X, Wang Z, Liu L: A variant of estrogen receptor-alpha, ER-alpha36 is expressed in human gastric cancer and is highly correlated with lymph node metastasis. Oncol Rep; 2010 Jul;24(1):171-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A variant of estrogen receptor-alpha, ER-alpha36 is expressed in human gastric cancer and is highly correlated with lymph node metastasis.
  • Gastric cancer is one of the most common cancers in the world; almost two-thirds of gastric cancer cases and deaths occur in less developed regions.
  • The molecular and cellular events during development of gastric cancer remain unclear.
  • Herein, we examined the expression of ER-alpha36, an ER-alpha variant, in established gastric cancer cell lines and specimens from 22 gastric cancer patients.
  • ER-alpha36 localization in gastric cancer cells was determined with an immunofluorenscence assay.
  • Both mRNA and protein of ER-alpha36 were detected in all established gastric cancer cell lines examined.
  • ER-alpha36 protein was expressed mainly on the plasma membrane and in the cytoplasm of the established gastric cancer cells.
  • ER-alpha36 expression is highly correlated with lymph node metastasis in human gastric cancer (P<0.05).
  • The estrogen receptor variant ER-alpha36 is highly expressed in human gastric cancer.
  • ER-alpha36 expression may be used as a predictive marker for lymph node metastasis of gastric cancer.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Soc Trans. 2003 Feb;31(Pt 1):56-9 [12546653.001]
  • [Cites] Trends Endocrinol Metab. 2002 Oct;13(8):349-54 [12217492.001]
  • [Cites] FEBS Lett. 2003 Jul 3;546(1):17-24 [12829231.001]
  • [Cites] Cancer Res. 1982 Dec;42(12):5181-2 [7139622.001]
  • [Cites] Science. 1986 Mar 7;231(4742):1150-4 [3753802.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1376-9 [3948119.001]
  • [Cites] J Steroid Biochem. 1986 Jan;24(1):1-7 [3517497.001]
  • [Cites] Cancer. 1987 Apr 1;59(7):1328-32 [3545434.001]
  • [Cites] Br J Surg. 1991 Mar;78(3):334-6 [2021850.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):305-8 [2070329.001]
  • [Cites] Surg Today. 1992;22(5):421-5 [1421863.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):812-5 [8119771.001]
  • [Cites] Int J Cancer. 1994 Dec 15;59(6):761-4 [7989115.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30 [8650195.001]
  • [Cites] Gut. 1997 Apr;40(4):516-20 [9176081.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 4;336(4):1023-7 [16165085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9063-8 [16754886.001]
  • [Cites] Eur J Surg Oncol. 2007 Mar;33(2):195-201 [17046193.001]
  • [Cites] Anticancer Res. 2008 Jan-Feb;28(1B):479-83 [18383888.001]
  • [Cites] Methods Mol Biol. 2009;472:467-77 [19107449.001]
  • [Cites] FEBS Lett. 2009 Apr 17;583(8):1368-74 [19328202.001]
  • [Cites] Physiol Rev. 2001 Oct;81(4):1535-65 [11581496.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):594-5 [11794139.001]
  • [Cites] Cancer Lett. 2002 Feb 25;176(2):129-35 [11804739.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):665-9 [12679906.001]
  • (PMID = 20514458.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK070016; United States / NIDDK NIH HHS / DK / DK070016
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Protein Isoforms
  • [Other-IDs] NLM/ NIHMS382669; NLM/ PMC3380086
  •  go-up   go-down


91. Papaziogas B, Koutelidakis I, Tsiaousis P, Panagiotopoulou K, Paraskevas G, Argiriadou H, Atmatzidis S, Atmatzidis K: Carcinoma developing in ectopic pancreatic tissue in the stomach: a case report. Cases J; 2008;1(1):249
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma developing in ectopic pancreatic tissue in the stomach: a case report.
  • In this study, we describe the first case of endoepithelial carcinoma arising in a gastric heterotopic pancreas of a 56-year old woman in Greece.
  • Esophagogastroduodenoscopy revealed an ulcerated lesion in the gastric antrum, biopsies of which showed intense epithelial dysplasia with incipient malignant degeneration.
  • The pathology report of the distal gastrectomy specimen demonstrated a 2 cm in diameter ulcerative mass in the gastric antrum.
  • Microscopically, an endoepithelial (in situ) carcinoma of the gastric antrum was determined, which in places turned into an microinvasive endomucosal adenocarcinoma.
  • It also incidentally demonstrated heterotopic pancreatic ducts, detected within the mucosa to the muscularis propria of the same region of the stomach, in which an endoepithelial (in situ) carcinoma was evolving.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Z Gastroenterol. 1995 May;33(5):260-4 [7610694.001]
  • [Cites] Histopathology. 1992 May;20(5):433-5 [1587493.001]
  • [Cites] J Pediatr Surg. 1991 Nov;26(11):1289-92 [1812259.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):196-8 [2032610.001]
  • [Cites] Postgrad Med J. 1988 Oct;64(756):801-3 [3255924.001]
  • [Cites] Am J Gastroenterol. 1990 May;85(5):597-601 [2337064.001]
  • [Cites] Arch Pathol Lab Med. 2000 Aug;124(8):1196-200 [10923083.001]
  • [Cites] J Pediatr Surg. 1977 Aug;12(4):593-9 [894461.001]
  • [Cites] Can J Surg. 1976 Sep;19(5):413-4 [974927.001]
  • [Cites] Arch Surg. 1974 Dec;109(6):762-5 [4420439.001]
  • [Cites] J Korean Med Sci. 2004 Feb;19(1):145-8 [14966359.001]
  • [Cites] Can J Surg. 2001 Dec;44(6):407 [11764870.001]
  • [Cites] Pathol Int. 2001 Jul;51(7):549-54 [11472568.001]
  • [Cites] West J Med. 1981 Jul;135(1):57-62 [7257381.001]
  • (PMID = 18928565.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2577107
  •  go-up   go-down


92. Tsirlis TD, Kostakis A, Papastratis G, Masselou K, Vlachos I, Papachristodoulou A, Nikiteas NI: Predictive significance of preoperative serum VEGF-C and VEGF-D, independently and combined with Ca19-9, for the presence of malignancy and lymph node metastasis in patients with gastric cancer. J Surg Oncol; 2010 Nov 1;102(6):699-703
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive significance of preoperative serum VEGF-C and VEGF-D, independently and combined with Ca19-9, for the presence of malignancy and lymph node metastasis in patients with gastric cancer.
  • BACKGROUND: Cumulative evidence demonstrate that lymphangiogenic vascular endothelial growth factors (VEGF)-C and -D are over-expressed and associated to lymph node metastasis (LNM) in gastric cancer.
  • The aim of this study is to investigate whether preoperative serum levels of VEGF-C and VEGF-D could be useful tumor markers in patients with operable gastric adenocarcinoma.
  • METHODS: We prospectively examined serum samples from 40 patients and 40 non-cancer controls using enzyme-linked immunosorbent assay (ELISA).
  • RESULTS: In gastric cancer patients, preoperative VEGF-C was significantly lower as compared to controls and to postoperative VEGF-C (P < 0.001); preoperative VEGF-D was significantly higher as compared to controls and to postoperative VEGF-D (P < 0.001).
  • ROC curve analysis identified a VEGF-C/VEGF-D cut-off value of < 2.7 for the presence of gastric cancer, with 83% sensitivity and 75% specificity (P < 0.001).
  • CONCLUSION: Circulating levels of VEGF-C and VEGF-D could play a role as biomarkers for serological detection and staging in gastric cancer.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Stomach Neoplasms / blood. Stomach Neoplasms / pathology. Vascular Endothelial Growth Factor C / blood. Vascular Endothelial Growth Factor D / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20672317.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D
  •  go-up   go-down


93. Celio L, Sternberg CN, Labianca R, La Torre I, Amoroso V, Barone C, Pinotti G, Cascinu S, Di Costanzo F, Cetto GL, Bajetta E: Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Ann Oncol; 2009 Jun;20(6):1062-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study.
  • BACKGROUND: This clinical trial assessed the efficacy of pemetrexed combined with oxaliplatin (PEMOX) in patients with advanced gastric cancer (AGC).

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19218305.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glutamates; 0 / Organoplatinum Compounds; 04Q9AIZ7NO / Pemetrexed; 04ZR38536J / oxaliplatin; 5Z93L87A1R / Guanine
  •  go-up   go-down


94. Yamaki S, Iwata S, Ohtsuka K, Kitaoka A, Masumoto H, Katoh H: [A case report of curative resection for gastric cancer with peritoneal dissemination successfully treated by combined chemotherapy of S-1 and paclitaxel]. Gan To Kagaku Ryoho; 2008 May;35(5):821-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of curative resection for gastric cancer with peritoneal dissemination successfully treated by combined chemotherapy of S-1 and paclitaxel].
  • The patient was a 54-year-old female with gastric cancer.
  • The S-1/PTX combination chemotherapy was thought to be effective for gastric cancer with peritoneal dissemination and made curative operation possible in this case.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Peritoneal Neoplasms / pathology. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487921.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


95. Matsuzaki T, Yashiro M, Kaizaki R, Yasuda K, Doi Y, Sawada T, Ohira M, Hirakawa K: Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci; 2009 Dec;100(12):2402-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer.
  • The aim of this study is to clarify the benefit of combination chemotherapy in gastric cancer based on a cell-signal inhibitor and an anticancer drug.
  • Two scirrhous gastric cancer cell lines and two non-scirrhous gastric cancer cell lines were used.
  • The proliferation of cancer cells was examined by MTT assay and in vivo study.
  • The apoptosis of cancer cells and the expression of apoptosis-related molecules were examined by flow cytometry, real-time PCR, and immunostaining. mTOR inhibitors with 5FU showed a synergistic antiproliferative effect in scirrhous gastric cancer, whereas the other signal inhibitors showed no synergistic effect with any anticancer drugs. mTOR inhibitor decreased the IC(50) of 5FU and increased the apoptosis rate in scirrhous gastric cancer cells, but not in non-scirrhous gastric cancer cells.
  • The pan-caspase inhibitor, zVAD-fmk, inhibits apoptosis induced in combination with 5FU and mTOR inhibitor. mTOR inhibitor decreased dihydropyrimidine dehydrogenase, thymidylatesynthase, and bcl-2 expression, and increased caspase-3 and p21 expression of scirrhous gastric cancer cells, but did not affect those of non-scirrhous gastric cancer cells.
  • These findings suggest that mTOR inhibitor interacts with 5FU in a synergistic manner in scirrhous gastric cancer cells by the activation of the apoptosis signal.
  • Therefore, mTOR inhibitor is a promising therapeutic agent in combination with 5FU in scirrhous gastric cancer.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / administration & dosage. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764996.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Intracellular Signaling Peptides and Proteins; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; U3P01618RT / Fluorouracil
  •  go-up   go-down


96. Luo F, Tao D, Zhao P, Zhang L, Jia Y, Zhang W: [Comparison of extracted proteins of human stomach tumor and normal tissues with liquid chromatography-multistage mass spectrometry]. Se Pu; 2010 Jan;28(1):34-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of extracted proteins of human stomach tumor and normal tissues with liquid chromatography-multistage mass spectrometry].
  • Screening of tumor markers by proteomic technology is the research focus and key of early diagnosis of stomach cancer study.
  • Based on the difference of hydrophobicity, RP-HPLC separation was performed to reduce the complexity of stomach cancer tissue and normal tissue samples, separately.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458917.001).
  • [ISSN] 1000-8713
  • [Journal-full-title] Se pu = Chinese journal of chromatography
  • [ISO-abbreviation] Se Pu
  • [Language] CHI
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proteins
  •  go-up   go-down


97. Yamamichi N, Inada K, Ichinose M, Yamamichi-Nishina M, Mizutani T, Watanabe H, Shiogama K, Fujishiro M, Okazaki T, Yahagi N, Haraguchi T, Fujita S, Tsutsumi Y, Omata M, Iba H: Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. Cancer Res; 2007 Nov 15;67(22):10727-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state.
  • We observed frequent loss of Brm expression but not of BRG1 in human gastric cancer cell lines.
  • Brm immunostaining of 89 primary gastric cancers showed an obvious reduction in 60 cases (67%) and a severe decrease in 37 cases (42%).
  • Loss of Brm is frequent in the major gastric cancer types (well- or moderately-differentiated tubular adenocarcinoma and poorly-differentiated adenocarcinoma) and positively correlates with the undifferentiated state.
  • Among the minor gastric cancer types, Brm expression persists in signet-ring cell carcinoma and mucinous adenocarcinoma, but a marked decrease is observed in papillary adenocarcinoma.
  • Intestinal metaplasia never shows decreased expression, indicating that Brm is a valid marker of gastric oncogenesis.
  • In contrast, BRG1 is retained in most cases; a concomitant loss of BRG1 and Brm is rare in gastric cancer, contrary to other malignancies.
  • Via regulating such genes important for gut differentiation, Brm should play significant roles in determining the histologic features of gastric malignancy.
  • [MeSH-major] Adenocarcinoma / metabolism. Gene Expression Regulation, Neoplastic. Microfilament Proteins / biosynthesis. Stomach Neoplasms / metabolism. Transcription Factors / biosynthesis. Transcription Factors / genetics
  • [MeSH-minor] Cell Differentiation. Cell Line, Tumor. Colorectal Neoplasms / metabolism. Enzyme Inhibitors / pharmacology. Epigenesis, Genetic. Gastric Mucosa / metabolism. Gene Expression Profiling. Histone Deacetylase Inhibitors. Humans. Models, Biological

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006815.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Microfilament Proteins; 0 / SMARCA2 protein, human; 0 / Transcription Factors; 0 / villin
  •  go-up   go-down


98. Zhao F, Zhang Q, Kang C, Cui X, Wang T, Xu P, Zhou X, Liu J, Song X: Suppression of matrix metalloproteinase-9 expression by RNA interference inhibits SGC7901 gastric adenocarcinoma cell growth and invasion in vitro and in vivo. Med Oncol; 2010 Sep;27(3):774-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of matrix metalloproteinase-9 expression by RNA interference inhibits SGC7901 gastric adenocarcinoma cell growth and invasion in vitro and in vivo.
  • Up-regulated MMP-9 promotes growth and invasion of gastric adenocarcinomas.
  • The present study is to block MMP-9 expression in gastric adenocarcinoma cells in order to inhibit tumor growth and invasion.
  • Small interference RNAs (siRNA) targeted on human MMP-9 were used to suppress gene expression in SGC7901 human gastric adenocarcinoma cells.
  • Our results demonstrate that MMP-9 targeted RNAi is able to successfully suppress MMP-9 gene expression and inhibit cell growth and invasion of SGC7901 gastric adenocarcinoma in vitro and in vivo.
  • MMP-9 is a potential therapeutic target for gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / therapy. Genetic Therapy. Matrix Metalloproteinase Inhibitors. Neoplasm Proteins / antagonists & inhibitors. Oligoribonucleotides, Antisense / therapeutic use. RNA Interference. RNA, Small Interfering / therapeutic use. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1399-408 [16170032.001]
  • [Cites] Drug Discov Today. 2001 Mar 1;6(6):303-315 [11257582.001]
  • [Cites] Front Biosci. 2006 May 01;11:1696-701 [16368548.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2008 Jan 1;88(1):36-9 [18346378.001]
  • [Cites] Nature. 1996 Sep 19;383(6597):247-50 [8805698.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Best Pract Res Clin Rheumatol. 2006 Oct;20(5):983-1002 [16980219.001]
  • [Cites] Braz J Med Biol Res. 2005 Oct;38(10):1521-30 [16172745.001]
  • [Cites] Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):75-86 [17449137.001]
  • [Cites] J Pathol. 2003 Jul;200(4):423-8 [12845610.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4956-64 [17510426.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Jan;28(1):12-24 [12495928.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2307-16 [17657740.001]
  • [Cites] Matrix Biol. 2007 Oct;26(8):587-96 [17669641.001]
  • [Cites] Trends Cell Biol. 2005 May;15(5):251-8 [15866029.001]
  • [Cites] Adv Drug Deliv Rev. 2000 Oct 31;44(1):3-21 [11035194.001]
  • [Cites] World J Gastroenterol. 2007 Nov 28;13(44):5857-66 [17990351.001]
  • [Cites] Front Biosci. 2006 Jan 01;11:544-69 [16146752.001]
  • [Cites] Cardiovasc Res. 2006 Feb 15;69(3):562-73 [16405877.001]
  • [Cites] Int J Oncol. 2007 Nov;31(5):1039-50 [17912429.001]
  • [Cites] Trends Biochem Sci. 2005 Feb;30(2):106-14 [15691656.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3633-41 [18060021.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):728-35 [8573349.001]
  • [Cites] Cell. 2002 Sep 6;110(5):563-74 [12230974.001]
  • [Cites] Cell. 2003 Oct 17;115(2):199-208 [14567917.001]
  • [Cites] World J Gastroenterol. 2008 Jan 21;14(3):421-7 [18200665.001]
  • [Cites] Zhonghua Yu Fang Yi Xue Za Zhi. 2006 Nov;40(6):405-8 [17313740.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):21882-92 [15824107.001]
  • [Cites] Cell. 2004 Jul 9;118(1):57-68 [15242644.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6469-79 [17085661.001]
  • [Cites] Neuron Glia Biol. 2004 May;1(2):165-76 [16804563.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):558-64 [15363807.001]
  • [Cites] World J Gastroenterol. 2005 Sep 28;11(36):5592-600 [16237750.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1624-36 [12697889.001]
  • [Cites] J Biol Chem. 1989 Oct 15;264(29):17213-21 [2551898.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2008 May 01;13(5):E275-80 [18449109.001]
  • (PMID = 19680827.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 0 / Neoplasm Proteins; 0 / Oligoribonucleotides, Antisense; 0 / Proliferating Cell Nuclear Antigen; 0 / RNA, Small Interfering; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


99. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E, Arbeitsgemeinschaft Internistische Onkologie: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol; 2008 Mar 20;26(9):1435-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
  • PURPOSE: This study was designed to compare fluorouracil, leucovorin, and oxaliplatin with fluorouracil, leucovorin, and cisplatin in patients with advanced gastric cancer.
  • PATIENTS AND METHODS: Patients with previously untreated advanced adenocarcinoma of the stomach or esophagogastric junction were randomly assigned to receive either fluorouracil 2,600 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2), and oxaliplatin 85 mg/m(2) (FLO) every 2 weeks or fluorouracil 2,000 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2) weekly, and cisplatin 50 mg/m(2) every 2 weeks (FLP).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Esophagogastric Junction. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349393.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; PFL protocol
  • [Investigator] Al-Batran SE; Jäger E; Atmaca A; Pauligk C; Probst S; Görner M; Hartmann JT; Schmalenberg H; Höffken K; Hollerbach S; Hollerbach C; Hofheinz R; Rethwisch V; Eimermacher H; Seipelt G; Homann N; Wagner T; Wilhelm G; Stoehlmacher J; Schuch G; Bokemeyer C; Derigs HG; Flohr T; Hegewisch-Becker S; Rummel M; Mitrou P; Grossmann J; Quasdorff SH; Knuth A; Genth K; Fach M; Schwemer D; Fritz M; Andus T; Kröning H; Brecht A; Fritze D; Kojouharoff G; Hahnfeld S; Lebahn H; Maiwirth F; Graubner M; Stiegler T; Blau W; Weh HJ; Rossol S; Hahn M; Ko Y; Neuhaus T; Stauch M; Dippold W
  •  go-up   go-down


100. Kim YG, Jang BI, Kim TN: A matched case-control study of a novel Acid-pump antagonist and proton-pump inhibitor for the treatment of iatrogenic ulcers caused by endoscopic submucosal dissection. Gut Liver; 2010 Mar;4(1):25-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We reviewed the medical records of patients who underwent endoscopic submucosal dissection (ESD) for gastric neoplasia at Yeungnam University Hospital between January 2008 and May 2009.
  • In the revaprazan group, only one patient had stage H2 disease: a 54-year-old man with a 5.5-cm lesion after ESD of the ulcer, type IIa early gastric cancer, and adenocarcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 1992 May;33(5):617-21 [1319381.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Jul;326(1):163-70 [18411413.001]
  • [Cites] Gastroenterology. 1992 Aug;103(2):407-13 [1634059.001]
  • [Cites] Gastroenterology. 1992 Feb;102(2):695-8 [1732139.001]
  • [Cites] Dig Dis Sci. 1988 May;33(5):619-24 [3282850.001]
  • [Cites] Biochem Pharmacol. 1995 Nov 9;50(10):1543-9 [7503755.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1995;35:277-305 [7598495.001]
  • [Cites] Dig Dis Sci. 1996 Oct;41(10):2039-47 [8888719.001]
  • [Cites] Free Radic Biol Med. 1996;21(5):727-31 [8891677.001]
  • [Cites] Pharmacotherapy. 1997 Jan-Feb;17(1):22-37 [9017763.001]
  • [Cites] J Clin Biochem Nutr. 2008 May;42(3):191-6 [18545640.001]
  • [Cites] Dig Dis Sci. 2009 Jul;54(7):1494-9 [19005762.001]
  • [Cites] Am J Gastroenterol. 2009 May;104(5):1130-4 [19337238.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:74-81 [10807407.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Dec;281(6):G1502-11 [11705756.001]
  • [Cites] J Clin Pharmacol. 2004 Jan;44(1):73-82 [14681344.001]
  • [Cites] Wound Repair Regen. 2004 Jan-Feb;12(1):93-9 [14974970.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):213-7 [15278047.001]
  • [Cites] Hum Mol Genet. 2004 Nov 15;13(22):2813-21 [15385447.001]
  • [Cites] Chin J Dig Dis. 2005;6(3):119-21 [16045601.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):685-9 [16082584.001]
  • [Cites] J Biol Chem. 2006 Aug 18;281(33):23740-7 [16754665.001]
  • [Cites] J Med Invest. 2007 Feb;54(1-2):83-90 [17380018.001]
  • [Cites] Am J Physiol. 1992 Jun;262(6 Pt 2):H1955-8 [1320341.001]
  • (PMID = 20479909.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871596
  • [Keywords] NOTNLM ; Acid pump antagonists / Endoscopic submucosal dissection / Proton pump inhibitors / Rabeprazole / Revaprazan
  •  go-up   go-down






Advertisement